  Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197480] 
 
Phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab 
(BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma 
 
Lead Investigator 
John Reneau, M.D., Ph.D. 
The Ohio State University Comprehensive Cancer Center â€” 
Arthur G. James Cancer Hospi [INVESTIGATOR_792768] J. Solove Research Institute 
 
IND Sponsor -Investigator 
Ryan A. Wilcox, M.D., Ph.D. 
University of Michigan Rogel Cancer Center 
 
Co-Investigators 
Shannon Carty, M.D. 
Sumana Devata, M.D.  
Tycel Phillips, M.D. 
Mark Kaminski, M.D. 
Tera Mayer, N.P.  
 
 
Statistician  
Philip Boonstra, Ph.D. 
  
Trial Management  
Big Ten CRC Administrative Headquarters at Hoosier Cancer Research Network, Inc.  
500 N. Meridian, Suite 100 
Indianapolis, IN [ZIP_CODE] 
  
Trial Support  
Bristol-Myers Squibb 
(CA025-003) 
 
Investigational New Drug (IND) Number : 
142651 
   
Initial Protocol Version Date: 02JAN2019  
 Protocol Amendment Version D ate:  
08FEB2019 20SEP2019 revised  (current)  
  
Big Ten Cancer Research Consortium     Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 2 of 84 PROTOCOL SIGNATURE [CONTACT_859393]-1R monoclonal antibody cabiralizumab ( BMS-
986227) in patients with relapsed/refractory peripheral T cell lymphoma 
 
 
VERSION DATE:  20SEP2019 revised  
I confirm I have read this protocol, I understand it, and I will work according to this protocol and to the 
ethical principles stated in the latest version of the Declaration of Helsinki, the applicable guidelines for good clinical practices, whichever provides the greater protection of the individual.  I will accept the monitorâ€™s overseeing of the study.  I will promptly submit the protocol to applicable ethical review board(s). 
 
 
 
 
____________________________________ ________________________ 
 Signature [CONTACT_129335]  
 
 ____________________________________  Site Investigator Name (printed) 
  ____________________________________  Site Investigator Title  
  ____________________________________  Name [CONTACT_4004]  
  ____________________________________  Location of Facility (City and State)  
   
PLEASE EMAIL COMPLETED FORM TO BIG TEN CRC  
ADMINISTRATIVE HEADQUARTERS  
   
Big Ten Cancer Research Consortium     Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 3 of 84 SYNOPSIS  
TITLE Phase II study of nivolumab and the antagonistic CSF -1R monoclonal antibody 
cabiralizumab ( BMS-986227) in patients with relapsed/refractory peripheral T 
cell lymphoma  
PHASE  II 
OBJECTIVES  Primary Objective s:  
1) To estimate objective response (OR) rate (ORR)  to nivolumab and 
cabiralizumab in relapsed/refractory peripheral T cell lymphoma (PTCL) 
by [CONTACT_859346] 4 months 
2) To estimate complete  response (CR) rate  (CRR) to nivolumab and 
cabiralizumab in relapsed/refractory peripheral T cell lymphoma (PTCL) 
by [CONTACT_859346] 4 months 
Secondary Objectives:   
1) To estimate ORR and CRR of this combination by [CONTACT_165224] 4 
months. 
2) To estimate the best OR (including PR and CR) at any time on trial by [CONTACT_859347] 
3) To estimate  progression free survival (PFS), disease control rate (DCR),  
duration of response (DOR), and time to next treatment (TNT) . 
4) To evaluate the safety and tolerability of the combination of cabiralizumab and nivolumab. 
Exploratory Objectives: 
1) To determine l ymphoma associated macrophage (LAM) , regulatory T cell  
(Treg), and cytotoxic T lymphocyte (CTL)  densities (before and during 
treatment) as pharmacodynamic and prognostic biomarkers. 
2) To determine l ymphoma cell  and tumor microenvironment expression of 
PD-L1 and CSF-1R as pharmacodynamic and prognostic biomarkers. 
3) To examine the abundance of â€œexhaustedâ€ T cells in the peripheral blood as a pharmacodynamic and prognostic biomarker. 
4) To evaluate the feasibility and utility of minimal residual disease monitoring throughout treatment as a pharmacodynamic and prognostic biomarker. 
5) To evaluate the role of myeloid derived suppressor cells as a pharmacodynamic and prognostic biomarker. 
6) To biobank diagnostic biopsy specimens and PBMC for future correlative 
studies. 
STUDY DESIGN  Open label, single arm, non -randomized trial  
KEY ELIGIBILITY CRITERIA  Inclusion criteria:  
1) Able to voluntarily provide written IRB-approved informed consent. 
2) At least 18 years of age or older at the time of enrollment.  
3) ECOG Performance Status of  0-2 
4) Histologic confirmation of peripheral T -cell lymphoma (PTCL)  with 
measurable disease on imaging. Adult T- cell leukemia/lymphoma 
(ATLL) are excluded . 
Big Ten Cancer Research Consortium     Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 4 of 84 5) Documented disease progression after receiving at least two prior 
therapeutic regimen s including brentuximab vedotin in patients with 
CD30 positive disease (defined as >10% CD30 positive cells). 
6) Prior cancer treatment must be completed at least [ADDRESS_1197481] recovered from all treatment 
related toxicities (less than grade 3) or returned to baseline prior to 
treatment . Steroids at <10 mg prednisone equivalent daily allowed. 
7) Adequate hematological function: 
a. ANC â‰¥1,000 cel ls/uL 
b. Platelets â‰¥75,000 cells/uL 
8) Adequate renal function: 
a. Serum creatinine â‰¤1.[ADDRESS_1197482], or calculated creatinine clearance >30 mL/min.  
9) Adequate hepatic function:  
a. Bilirubin â‰¤1.5 times the specific institutional upper limit of normal (ULN) (except patients with Gilbert's syndrome, who must have 
total bilirubin <3 mg/dL)  
b. AST and ALT each â‰¤1.[ADDRESS_1197483] (or â‰¤2.[ADDRESS_1197484] in the presence of known or suspected hepatic involvement) 
10) Women of childbearing potential (WOCBP) must have a negative serum or urine preg nancy test (minimum sensitivity of 25 IU/L or 
equivalent units of human chorionic gonadotropin) performed at screening and within 24 hours prior to the start of study treatment. 
11) Females of childbearing potential must be willing to abstain from heterosexual  activity or use an effective method of contraception from 
the time of informed consent until [ADDRESS_1197485] 
12) Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving 
study drugs and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of [ADDRESS_1197486]. 
13) Able to understand and comply with study procedures. 
Exclusion Criteria:  
1) PTCL histology consistent with ATLL 
2) A history of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigatorâ€™s opi[INVESTIGATOR_1649], could affect the conduct of the study. 
3) Active infection requiring systemic therapy . 
4) Recent (<100 days) autologous stem cell transplant, or previous allogeneic stem cell transplant.  
5) Known positive test for hepatitis B surface antigen, hepatitis C, or HIV  
6) Pregnant or breastfeeding  female. 
7) Known additional malignancy that is active/progressive requiring treatment. Exceptions include: 
a. basal cell skin cancer  
Big Ten Cancer Research Consortium     Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 5 of 84 b. squamous cell skin cancer  
c. in situ cervical  cancer 
d. in situ bladder cancer 
8) Prior treatment with cabiralizumab  
9) Prior treatment with nivolumab or other medications within the 
checkpoint blockade family. 
Please see body of protocol for full exclusion criteria.  
STATISTICAL 
CONSIDERATIONS  We propose a two -stage design with co -primary endpoints of complete 
response (CR) and overall response (OR), testing a â€œboth-andâ€ null hypothesis against an â€œeither- orâ€ alternative hypothesis. Specifically, we 
posit that a CRR of 30% or ORR of 60% is achievable. Initially, 17 eligible patients will be followed for response. At this point, if fewer than 3 patients demonstrate CR (<18%) and fewer than 7 patients demonstrate OR (<41%), the trial will be stopped for futility. Otherwise, we will enroll an additional [ADDRESS_1197487] 7 patients (out of 33 total) demonstra te CR (21%) or at least 17 patients demonstrate OR 
(52%). When the true CRR and ORR are simultaneously no greater than 10% and 30%, respectively, this design will successfully conclude with probability at most 0.05 (one-sided type I error) and stop at the interim analysis with probability at least 0. 75.  When the true CRR is at least 30% 
or the true ORR is at least 60%, this design will successfully conclude with probability at least 0. 62 (power) and stop for futility at the interim analysis 
with probability at most 0.34. 
Multiple Grade 4+ adverse event (AE) stoppi[INVESTIGATOR_859317] [ADDRESS_1197488], enrollment will stop for any grade 4 
AE observed in  â‰¥7 (7/17=41%) patients. Second, enrollment will stop for 
grade 4 AE requiring discontinuation of treatment, as specified in the protocol, observed in  â‰¥3 (3/17=12%) of patients. Third, enrollment will stop if any Grade [ADDRESS_1197489] 17 subjects.  
Peripheral T -cell lymphoma response and progression will be assessed 
using the provisional Lugano lymphoma response to immunomodulatory therapy criteria (LYRIC) . Additional secondary endpoints include response 
by [CONTACT_165219], PFS, DCR, DOR, and TNT. Safety assessments will consist of the surveillance and recording of AEs and documentation of physical examination findings and laboratory data. Type, incidence, 
severity, seriousness, and relatedness of adverse events will be recorded.  
TOTAL 
NUMBER OF 
SUBJECTS  33 
ESTIMATED 
ENROLLMENT 
PERIOD  18 months 
ESTIMATED 
STUDY 
DURATION  60 months 
  
Big Ten Cancer Research Consortium     Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 6 of 84 TABLE OF CONTENTS  
 
Schema .............................................................................................................................................8  
1. Background and Rationale .......................................................................................................9  
1.1 Background: Peripheral T Cell Lymphoma (PTCL) .......................................................9  
1.2 Background: Checkpoint blockade (CPB) in PTCL ......................................................10  
1.3 Background: Lymphoma- associated macrophages (LAM) in PTCL  ............................[ADDRESS_1197490] Registration  ...............................................................................................................26  
5. Treatment Plan  .......................................................................................................................26  
5.1 Pre-medication and Hydration .......................................................................................26  
5.2 Nivolumab plus Cabiralizumab Administration  ............................................................27  
5.3 Concomitant Medications ..............................................................................................27  
5.4 Supportive Care .............................................................................................................27  
6. Toxicities and Dose Delays/Dose Modifications ...................................................................29  
6.1 Dose Delays/Dose Modifications ..................................................................................29  
6.2 Cabiralizumab and Nivolumab- Related Infusion Reactions..........................................30  
6.3 Protocol Therapy Discontinuation .................................................................................32  
6.4 Protocol Discontinuation ...............................................................................................33  
7. Study Calendar & Evaluations ...............................................................................................[ADDRESS_1197491] Overall Response ............................................................................40  
9.3 Definitions for Response Evaluation â€“ LYRIC criteria  .................................................40  
10. Drug Information ...............................................................................................................42  
10.1  Cabiralizumab  ................................................................................................................42  
10.2  Nivolumab......................................................................................................................43  
11. Adverse Events  ..................................................................................................................45  
11.1  Definitions ...................................................................................................................... 45 
Big Ten Cancer Research Consortium     Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 7 of 84 11.2  Reporting........................................................................................................................47  
12. Statistical Methods  .............................................................................................................49  
12.1  Study Design ..................................................................................................................49  
12.2  Endpoints .......................................................................................................................49  
12.3  Sample Size, Accrual, and Interim Futility Analysis  .....................................................50  
12.4  Assessment of Safety  .....................................................................................................52  
12.5  Assessment of Efficacy  ..................................................................................................52  
12.6  Data Analysis Plans  .......................................................................................................52  
13. Trial Management  ..............................................................................................................52  
13.1  Data and Safety Monitoring Plan (DSM P) ....................................................................[ADDRESS_1197492] (IRB) Approval ..................................................................[ADDRESS_1197493] of the Study .........................................................................................55  
15.3  Informed Consent Process .............................................................................................55  
16. References  ..........................................................................................................................56  
17. Appendices .........................................................................................................................61  
17.1  Management of toxicities  ...............................................................................................61  
17.2  Laboratory abnormalities  management ..........................................................................74  
17.3  Lugano staging criteria ..................................................................................................75  
17.4  Eastern Cooperative Group (ECOG) Performance Status Scale ...................................75  
17.5  LYRIC criteria for response  ...........................................................................................76  
17.6  Lugano 2014 response criteria .......................................................................................81  
%LJ7HQ&DQFHU5HVHDUFK&RQVRUWLXP   &OLQLFDO6WXG\3URWRFRO
    %7&5&+(0
6(3UHY &RQILGHQWLDO 3DJHRI6&+(0$


Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 9 of 84 1. BACKGROUND AND RATIONALE  
1.1 Background: Peripheral T Cell Lymphoma  (PTCL) 
Approximately 10-15% of non-Hodgkin lymphomas (NHL) are derived from mature (i.e. post- thymic) T 
lymphocytes [ 1]. The heterogeneity of these lymphomas and poor understanding of their pathogenesis 
continue to impede their classification and the development of novel therapeutic strategies. This is 
highlighted by [CONTACT_859348] T- cell lymphoma 
(PTCL) lacks any distinguishing characteristics and is designated by [CONTACT_265012] â€œPTCL, not otherwise specified (PTCL, NOS )â€ [1, 2]. While the development of combination 
immunochemotherapy (e.g. â€œR-CHOPâ€) has led to significant survival benefits in B- cell NHL, the 
PTCLs are associated with inferior responses to th erapy and overall survival [ 3]. In fact, the vast 
majority of PTCL patients will ultimately succumb to their disease, most within a few years of diagnosis [1, 2, 4]. Novel therapeutic strategies are needed if improved outcomes are to be achieved. The 
observation that PTCL incidence rates are increasing faster than almost any other subgroup of NHL further heightens this sense of urgency [ 5, 6]. 
 Anthracycline-based therapi[INVESTIGATOR_014] (e.g. CHOP) remain the mainstay of therapy for PTCL, even though the survival benefit associated with this approach remains suboptimal[ 2, 7]. More intensive induction 
regimens and consolidation with high-dose chemotherapy followed by [CONTACT_20375]- cell 
transplantation are frequently employed strategies, but primary refractory disease and ear ly relapses are 
common. Three novel agents, belinostat, pralatrexate and romidepsin, were granted FDA approval for relapsed/refractory PTCL and are associated with overall response rates of approximately 26% [8], 
29%[9] and 25-38%[ 10, 11], respectivel y. A complete response rate of ~11% is observed in patients 
treated with belinostat or pralatrexate as single agents. Durable complete remissions are rarely achieved 
with these agents. Consequently, the outlook for PTCL patients with relapsed/refractory disease remains grim, and novel therapeutic strategies are needed [12, 13].  
 While preliminary results with checkpoint blockade (CPB) are encouraging, it is likely that novel 
combinatorial strategies will be required to improve outcomes in these patien ts following CPB [ 14]. 
 Brentuximab vedotin also received FDA approved for the treatment of relapse d/refractory anaplastic 
large cell lymphoma (ALCL), a subtype of PTCL, based on phase II, open-label study of 58 patients. The overall response rate in this study was 86% with a complete response rate of 57% with a median duration of 13.2 months [ 15]. Grade 3/4 adverse events occurred in >10% of patients and included 
neutropenia, thrombocytopenia, and peripheral sensory neuropathy[ 15].  Another phase II, open- label, 
multicenter study evaluated the response rate of Brentuximab vedotin in relapsed CD30+ non-Hodgkin lymphomas which included PTCL and angioimmunoblastic T-cell lymphoma (AITL). The overall response rate in these cases was 41% with a complete response rate of 24% [16].  The duration of 
response is quite variable and short with the reported median duration of response of 7.6 months; however, the median duration of a complete response had not been reached at the time of the initial analysis[16].  Grade 3/[ADDRESS_1197494] common events [ 16]. Brentuximab is a promising 
treatment agent but the most significant limitation is the need for continued treatment which is limited by [CONTACT_859349]. Furthermore, the use of brentuximab within PTCL is limited to ALCL. Despi[INVESTIGATOR_859318], the outlook for PTCL patients with relapsed/refractory 
disease remains grim, and novel therapeutic strategies are needed.  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 10 of 84 1.2 Background: Checkpoint blockade (CPB) in PTCL  
While durable remissions with conventional chemotherapy are rarely achieved in relapsed/refractory T-
cell NHL [12, 13, 17 ], durable remissions are achieved with immunomodulatory therapi[INVESTIGATOR_014], including 
extracorporeal photopheresis (ECP) and inter feron-Î± [18]. While largely anecdotal, these observations 
suggest that host immunity, when properly harnessed, can lead to durable responses in selected patients. These observations, coupled with high- level PD-L1 expression in a substantial minority of patients, 
further provide a strong rationale for CPB in cutaneous T cell lymphoma (C TCL) and PTCL. While few 
of these patients have been included in early phase clinical trials and further experience with CPB in CTCL/PTCL is needed, few durable responses have been observed to date. Twenty- three CTCL/PTCL 
patients were enrolled in a phase Ib study with nivolumab in relapsed/refractory hematologic 
malignancies [19]. Among heavily pretreated (61% had received â‰¥4 prior therapi[INVESTIGATOR_014]) CTCL/PTCL 
patients enrolled in this study, no complete remissions and 4 partial remissions were observed, for an overall response rate of 17% [19]. While the median progression- free survival wa s 10 weeks for all 
patients, two responding CTCL patients achieved responses that were ongoing at 24+ and 50+ weeks. A single PTCL patient achieved a response that was ongoing at 18+ months. Preliminary data from an ongoing phase II study with pembrolizumab in relapsed/refractory mycosis fungoides (MF) and Sezary syndrome (SS) has been reported [20]. Among 24 patients enrolled, no complete remissions and eight 
partial remissions were observed, for an overall response rate (ORR) of 33%. Among these responses, four were in MF (44% ORR in MF) and four in Sezary syndrome (27% ORR in SS). Responses were observed in advanced-stage MF, including patients with tumor-stage disease (2/2, ORR 100%) and large-cell transformation (1/3, ORR 33%). While these preliminary results are encouraging, improved understanding of the genomic and immunologic landscapes may be needed to further optimize CPB in the T-cell lymphoproliferative disorders. 
1.3 Background: Lymphoma -associated macrophages (LAM) in PTCL  
Gene expression by [CONTACT_56927]- associated macrophages (LAM) and their density within the tumor 
microenvironment (TME) explain the variable natural history associated with many non-Hodgkin lymphomas. In most cancers, tumor- associated macrophages  (TAM) promote tumorigenesis and are 
alternatively polarized. A growing body of evidence highlights the role of various subsets of myeloid-derived cells, including LAM, in tumorigenesis, and further supports the rationale for their therapeutic targeting in PTCL [ 21-26]. LAM are abundant constituents of the TME in PTCL, where they promote 
chemotherapy resistance[ 21, 24, 26]. Upon activation and differentiation, normal CD4
+ T cells produce 
cytokines that regulate LAM biology, including type 1 (IFN-Î³) and type 2 (IL- 4, IL-13) cytokines, 
which lead to â€œclassicalâ€ and â€œalternativeâ€ pathways of LAM activation and functional polarization, respectively. Cytokines produced by [CONTACT_248261] T cells similarly promote LAM recruitment/expansion within the TME [21], their functional (â€œalternativeâ€) polarization [24], and PD-L1 expression [ 22]. For 
example, we have shown that IL-[ADDRESS_1197495] partially, PD -L1 (B7-H1) dependent. Collectively, this 
data suggests that depletion of LAM in the T- cell lymphomas may impair the growth and survival of 
malignant T cells and reverse immune suppression within the TME, potentially augmenting the efficacy of novel immunotherapi[INVESTIGATOR_014], including checkpoint blockade, as demonstrated in other tumor models[ 27].  
We have shown that PD -L1 is expressed by [CONTACT_248261] T cells in 5-33% of PTCL, depending on the 
histologic subtype examined[ 22]. More commonly, PD-L1 is expressed by [CONTACT_308091]-derived cells, 
including LAM, within the TME in 22-73% of PTCL subtypes[ 22]. PD-L1 suppresses T- cell immunity 
both directly and indirectly, by [CONTACT_859350]3
+ regulatory T cells (Treg) [22]. The 
extent to which immunomodulatory strategies, including LAM depletion, may improve responses to 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197496] been implicated in the recruitment and survival of LAM, 
colony-stimulating factor -1 (CSF-1, or M-CSF) is require d for normal macrophage homeostasis and 
viability. Mice lacking functional CSF-1 or nullizygous for CSF- 1 receptor (CSF -1R, c-fms, CD115) 
have a marked decrease in tissue resident macrophages. Therefore, inhibition of CSF- 1R has emerged as 
a rational therapeutic strategy in many solid tumors and hematologic malignancies[ 28-32]. We have 
demonstrated in pre- clinical in vitro studies that CSF -1R blockade prevents the generation of LAM in a 
variety of hematologic malignancies[ 33]. Neutralizing monoclonal antibodies ha ve also been utilized to 
deplete lymphoma-associated macrophages and inhibit lymphoma progression in preclinical models[ 30, 
34], and bolster response rates to checkpoint blockade[ 35].  
In addition to its role in regulating LAM, CSF-1R may directly promote the growth and survival of malignant T cells due to is aberrant expression by [CONTACT_248261] T cells and B cells in classical Hodgkin lymphoma ( cHL)[36]. We have observed that CSF-1R, the expression of which is normally confined to 
myeloid-lineage cells, is aberrantly expressed in various T-cell lymphomas (and cHL). CSF-1R 
expression was examined by [CONTACT_795250] a large cohort of PTCL specimens, and its expression (2-3+, >50% of PTCL cells) observed in 32% of PTCL, NOS , 69% of ALCL, and 40% of 
CTCL. Expression was rare in AITL. This lineage-inappropriate expression of CSF- 1R is likely 
explained by [CONTACT_859351][INVESTIGATOR_859319]- terminal repeat that drives 
transcription of an aberrant CSF-1R transcript[ 36]. CSF-1R signaling regulates cell growth, survival, 
and motility by [CONTACT_859352], including PI3K/AKT, ERK, and NF- ÎºB. 
Therefore, CSF -1R may similarly promote the growth and survival of malignant T cells. To address that 
possibility, loss -of-function studies were performed in CSF -1R-expressing T -cell lymphoma cell lines 
that have been lentivirally transduced with an inducible non-targeting or CSF-1R-targeting shRNAs. We have shown that CSF-1R knockdown significantly inhibits cell growth and proliferation in these c ells 
(data not shown). When CSF-1R
+ PTCL cell lines were grown as xenografts in immunodeficient (NSG) 
mice, administration of PLX3397 (a CSF-1R kinase inhibitor) significantly impaired tumor growth compared with sham treated controls. Further studies to elucidate the signaling mechanism(s) exploited by [CONTACT_38247]-1R when expressed by [CONTACT_248261] T cells are ongoing, using genetic and pharmacologic approaches.  
The median overall survival of relapsed/refractory PTCL in patients that are not candidates for high-dose therapy and autologous stem-cell transplantation is <6 months[ 12, 13]. The dismal outcomes 
observed in relapsed/refractory PTCL are explained, at least in part, by [CONTACT_62891]-rate of chemotherapy resistance and high proliferation rates observed. The aggressive behavior of these lymphomas poses a challenge for immunotherapeutic strategies, as disease progression may outpace the host anti-tumor immune response elicited by [CONTACT_859353], including checkpoint blockade, leading to cytokinetic failure. Therefore, therapeutic strategies, including CSF-1R inhibition, that may bolster anti-tumor immunity (upon LAM depletion) and slow the rate of disease progression (due to inhibition of CSF-1Râ€™s cell-autonomous effects on malignant lymphocytes) are e xtremely attractive.  
1.[ADDRESS_1197497] of Care   
Anthracycline-based therapi[INVESTIGATOR_014] (e.g. CHOP) remain the mainstay of therapy for PTCL, even though the survival benefit associated with this approach remains suboptimal[ 2, 7]. More intensive induction 
regimens and consolidation with high-dose chemotherapy followed by [CONTACT_20375]- cell 
transplantation are frequently employed strategies, but primary refractory disease and early relapses are 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 12 of 84 common. Three novel agents, belinostat, pralatrexate and romidepsin, were granted FDA approval for 
relapsed/refractory PTCL and are asso ciated with overall response rates of approximately 26% [ 8], 
29%[9] and 25-38%[ 10, 11], respectivel y. A complete response rate of ~11% is observed in patients 
treated with belinostat or pralatrexate as single agents. Durable complete remissions are rarely achieved 
with these agents. Consequently, the outlook for PTCL patients with relapsed/refractory disease remains grim, and novel therapeutic strategies are needed [12, 13].  
1.[ADDRESS_1197498] current pre- clinical and clinical  information on nivolumab, please refer to the 
Investigatorâ€™s Brochure (IB). IB version 16 was used in the development of this protocol.   Mechanism of Action Nivolumab (also referred to as BMS -936558 or MDX1106) is a human monoclonal antibody (HuMAb; 
immunoglobulin G4 [IgG4]-S228P) that targets the programmed death- 1 (PD-1) cluster of 
differentiation 279 (CD279) cell surface membrane receptor. PD- 1 is a negativ e regulatory molecule 
expressed by [CONTACT_93247] T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed deathâ€“ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD -1 and its ligands promotes immune responses and antigen- specific T -cell 
responses to both foreign antigens as well as self-antigens.   Pharmacokinetics The pharmacokinetics (PK) of nivolumab was studied in subjects over a dose range of 0.1 to 10 mg/kg administered as a single dose or as multiple doses of nivolumab every 2 or 3 weeks. The geometric mean (CV%) clearance (CL) was 9.5 mL/h (49.7%), geometric mean volume of distribution at steady state (Vss) was 8.0 L (30.4%), and geometric mean elimination half- life (t1/2) 
was 26.7 days (101%). Steady-state concentrations of nivolumab were reached by 12 weeks when administered at 3 mg/kg Q2W, and systemic accumulation was approximately 3-fold. The exposure to nivolumab increased dose proportionally over the dose range of 0.1 to 10 mg/kg administered every [ADDRESS_1197499]  on the CL of nivolumab: age (29 to 87 years), gender, race, 
baseline LDH, PD -L1. A PPK analysis suggested no difference in CL of nivolumab based on age, 
gender, race, solid tumor type, baseline tumor size, and hepatic impairment. Although E COG status, 
baseline glomerular filtration rate (GFR), albumin, body weight, and mild hepatic impairment had an effect on nivolumab CL, the effect was not clinically meaningful. PPK analysis suggest that nivolumab CL in subjects with cHL was approximately 32% lower relative to subjects with NSCLC; however, the lower CL in cHL subjects was not considered to be clinically relevant as nivolumab exposure was not a significant predictor for safety risks for these patients. When nivolumab is administered in combi nation with ipi[INVESTIGATOR_125],  the CL of nivolumab was increased by 24%, whereas 
there was no effect on the clearance of  ipi[INVESTIGATOR_125]. Additionally, PPK and exposure response 
analyses have been performed to support use of 240 mg Q2W dosing in addition to the 3 mg/kg Q2W regimen. A flat dose of nivolumab 240 mg Q2W was selected since it is identical to a dose of 3 mg/kg for subjects weighing 80 kg, the observed median body weight in nivolumab- treated cancer patients. 
Using a PPK model, the overall distributions of nivolumab exposures (Cavgss, Cminss, Cmaxss, and Cmin1) are  comparable after treatment with either 3 mg/kg or 240 mg nivolumab. The predicted 
range of nivolumab exposures (median and 90% prediction intervals) resulting from a 240 mg flat 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 13 of 84 dose across the 35 to 160 kg weight range is maintained well below the corresponding exposures 
observed with the well tolerate d 10 mg/kg nivolumab Q2W dosage. 
 Safety  
The overall safety experience with nivolumab, as a monotherapy or in combination with other therapeutics, is based on experience in approximately 16,[ADDRESS_1197500] advanced combination under development is nivolumab + ipi[INVESTIGATOR_162] b, which is approved in subjects with 
unresectable or metastatic melanoma, and being studied in multiple tumor types. Results to date 
suggest that the safety profile of nivolumab+ipi[INVESTIGATOR_859320]. The nature of the AEs is similar to that observed with either agent  used as monotherapy; however, both frequency and severity of most AEs are 
increased with the combination.   Across all studies conducted to date, drug- related AE s have included pulmonary toxicity, renal 
toxicity (including acute renal failure), endocrine abnormalities, GI toxicity, dermatologic toxicity 
(including rash), and hepatotoxicity. For nivolumab monotherapy and combination therapy, the majority of these A Es have been managed  successfully with supportive care and, in more severe 
cases, a combination of dose delay, permanent discontinuation, and/or use of corticosteroids or hormone replacement therapy (endocrinopathies) as instructed in the management guidelines provided in Appendix 17.1.  Summary of relevant clinical studies The PK, clinical activity, and safety of nivolumab have been assessed in approximately [ADDRESS_1197501] received ni volumab 
monotherapy in single- or multiple -dose Phase 1/2/3 studies or studies with nivolumab in 
combination with other therapeutics (ipi[INVESTIGATOR_125], cytotoxic chemotherapy, anti-angiogenics, and targeted therapi[INVESTIGATOR_014]).   
 Rationale for starting dose The starting dose of nivolumab (240 mg every 2 weeks) has been chosen based on previous phase I and II data regarding safety and efficacy of nivolumab. This is the FDA approved dosing in numerous other tumor types including cHL.  Metabolism and r oute(s) of elimination  
Nivolumab is an IgG4 monoclonal antibody, which is eliminated by [CONTACT_859354]-HEM16-085 
20SEP2019 rev. Confidential Page 14 of 84 other antibodies, namely by [CONTACT_105]- specific catabolism (mainly by [CONTACT_859355])[37]. Steady -state concentrations of nivolumab were reached by [CONTACT_3450] 12 weeks 
when administered at 3 mg/kg every 2 weeks, and systemic accumulation was approximately 3.7-
fold. The exposure to nivolumab increased dose proportionally over the dose range of 0.1 to 10 mg/kg administered every [ADDRESS_1197502] on the clearance 
of nivolumab: age (29 to 87 years), gender, race, b aseline LDH, PD -L1, solid tumor type, baseline 
tumor size, and hepatic impairment. Although ECOG status, baseline glomerular filtration rate  
(GFR), albumin, and body weight had an effect on nivolumab CL, the effect was not clinically meaningful. PPK analysis suggested that nivolumab CL in subjects with cHL was approximately 32% lower relative to subjects with NSCLC; however, the lower CL in cHL subjects was not considered to be clinically relevant as nivolumab exposure was not a significant predictor for sa fety risks for these 
patients.  
 Drug interactions Although monoclonal antibodies are not direct inhibitors/inducers of metabolizing enzymes, recent literature reports suggest that therapeutic proteins that are modulators of cytokines may indirectly affect expression of cytochrome (CYP) enzymes [38]. The indirect drug-drug interaction potential of 
nivolumab was assessed using systemic cytokine modulation data for cytokines known to modulate CYP enzymes, at single and multiple doses of 0.3 to 10 mg/kg Q3W from CA209009. There were no meaningful changes in cytokines known to have indirect effects on CYP enzymes across all dose levels of nivolumab (0.3, 2 and 10 mg/kg) during the course of treatment. This  lack of cytokine modulation 
suggests that nivolumab has no or low potential for modulating CYP enzymes, thereby [CONTACT_124439] a low risk of therapeutic protein-drug interaction. Nivolumab is an IgG4 monoclonal antibody, which is eliminated by [CONTACT_537519], namely by [CONTACT_105]- specific catabolism 
(mainly by [CONTACT_859356]) [37]. These enzymes are not known to be 
inhibited or induced by [CONTACT_8422], and therefore it is unlikely that other drugs will have an impact on the PK of nivolumab. 
1.[ADDRESS_1197503] current pre- clinical and clinical information on cabiralizumab, please refer to the 
Investigatorâ€™s Brochure (IB).  IB version 6 was used in the development of this protocol.  
 
Mechanism of Action Cabiralizumab ( BMS-986227) is a recombinant, humanized IgG4 monoclonal antibody that binds to 
human CSF1R. Binding of BMS -986227 to CSF1R antagonizes binding of CSF1 and IL34, the 2 
ligands to CSF1R, thereby [CONTACT_754436]1R. CSF1R signaling plays a fundamental role 
in the differentiation, maintenance, and function of monocytic lineage cells including monocytes, macrophages, and osteoclasts[ 39]. Two ligands have been identified for CSF1R, CSF1 and IL34. These 
2 ligands share little amino acid homology, but both bind similar regions of the CSF1R with similar affinities (reviewed in  [40]). 
 The tumor microenvironment, composed of non- cancer cells and stroma, is recognized as a major factor 
influencing the growth of tumor cells. Tumor- associated macrophages (TAMs) are particularly abundant 
in the tumor microenvironment and are thought to play a key role in promoting tumor growth. 
Substantial evidence suggests that TAMs are polarized towards an anti-inflammatory phenotype and 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 15 of 84 through the expression of cell surface T cell inhibitors and immunosuppressive soluble factors play a 
major role in inhibiting anti-tumor immune responses[ 41]. In the majority of tumors, TAMs are 
associated with a poor prognosis[ 42], making TAMs an attractive therapeutic target. Because CSF1 is a 
major survival factor for TAMs, targeting CSF1R through BMS -986227 should reduce tumor- associated 
macrophage-mediated immune suppression resulting in strengthening the anti-tumor response to immunotherapy. 
1.6.1 Cabiralizumab Clinical Summary  
The clinical summary of safety and efficacy is based on three clinical studies:  
1. Study FPA008-001 evaluated the safety of cabiralizumab as single or double ascending doses in 48 
healthy volunteers (36 received cabiralizumab and 12 received placebo). This study also evaluated the safety and efficacy of cabiralizumab administered as two or three doses, 14 days apart, in 18 rheumatoid arthritis (RA) subjects. This study has been completed. 
2. Study FPA008-002 is evaluating the safety and efficacy of cabiralizumab monotherapy for 6 months in approximately 40 subjects with pi[INVESTIGATOR_134364] (PVNS).  
3. Study FPA008-003 is evaluating the safety and efficacy of cabiralizumab as monotherapy and in combination with nivolumab in approxim ately 295 subjects with advanced cancers.  
Clinical Pharmacology Summary (Pharmacokinetics, Immunogenicity, and Pharmacodynamics)  The available PK, ADA, and nonclassical CD16+ monocyte status following cabiralizumab treatment with either monotherapy or in combination with nivolumab were characterized in three trials: FPA008 001, FPA008-002, and FPA008-003. The PK, ADA, and nonclassical CD16+ monocyte data from Study FPA008-003 are summarized below; data from Studies FPA008 001 and FPA008- 002 are presented i n 
the cabiralizumab IB. 
 The PK profile of cabiralizumab is characterized by [CONTACT_859357], with the latter likely mediated by [CONTACT_38220]1R on cells. As monocyte and macrophage cells are dependent on CSF1R for viability, these target -bearing cells are reduced in number following cabiralizumab 
treatment, resulting in a decrease of target -mediated clearance. Once target mediated clearance is 
saturated at high or repeat doses, cabiralizumab clearance is similar to other human IgG antibodies.  Study FPA008-003 â€“ Advanced Cancer (Cabiralizumab Monotherapy) In Phase 1a, subjects with cancer received cabiralizumab at doses of 2, 4, and 6 mg/kg Q2W as monotherapy and 1, 2, and 4 mg/kg Q2W in combination with 3 mg/kg nivolumab Q2W. There were a total of 25 subjects (n = 16 for monotherapy and n = 9 for combination treatment) with PK data as of [ADDRESS_1197504] dose in cancer subjects at 2, 4, and 6 mg/kg as monotherapy or at 1, 2, and 4 mg/kg in combination with nivolumab, Cmax increased dose proportionally, while AUC and Cmin increased more than dose proportionally, suggesting target- mediated clearance. Accumulation was observed for 
Cmax and Cmin with â‰¥ 2 mg/kg Q2W dosing. Exposures were similar at 4 mg/kg for cabiralizumab as monotherapy and in combination with nivolumab (limited data).  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 16 of 84 Assessment of nonclassical CD16+ monocytes in Study FPA008-003 has been evaluated in cohorts 
receiving 2, 4, or 6 mg/kg cabiralizumab monotherapy. In addition, assessment of nonclassical CD16+ monocytes has been evaluated in cohorts receiving a combination of 1, 2, or 4 mg/kg cabiralizumab with 3 mg/kg nivolumab. In the 2 mg/kg monotherapy cohort, cabiralizumab reduced nonclassical CD16+ monocytes throughout the 2-week dosing interval in 2 of 3 subjects evaluated. In the 4 mg/kg monotherapy cohort, cabiralizumab reduced nonclassical CD16+ monocytes throughout the 2- week 
dosing interval in [ADDRESS_1197505] who is evaluable. In the 6 mg/kg monotherapy cohort of ca biralizumab, all 
subjects showed reduction of nonclassical CD16+ monocytes through the 2-week dosing interval. End-of-treatment follow -up data are pending.  
 In the cohort receiving the combination of cabiralizumab at 1 mg/kg plus nivolumab, nonclassical CD16+ monocytes were reduced at 72 hours, but reduction was not maintained through the dosing interval. Nonclassical CD16+ monocytes returned to baseline levels in one subject and increased above baseline levels in two subjects. In the cohort receiving the combination of cabiralizumab at 2 mg/kg plus nivolumab, nonclassical CD16+ monocytes were reduced within [ADDRESS_1197506] dose. However, in 2 of the 3 subjects dosed with 2 mg/kg, cabiralizumab in combination with nivolumab was insufficien t to 
reduce nonclassical CD16+ monocytes throughout the 2-week dosing interval. In the cohort receiving 4 mg/kg cabiralizumab plus nivolumab, nonclassical CD16+ monocytes were reduced below the detection limits of the assay in all 3 subjects. Insufficient end-of-treatment follow -up data are available at this 
time. 
 Based on a review of PK and PD, the recommended dose for this study has been chosen as 4 mg/kg cabiralizumab in combination with  [ADDRESS_1197507] been treated in Study FPA008-003; [ADDRESS_1197508] been treated in the Phases 1a 
and 1b dose-expansion combination cohorts. A total of 265 subjects across the study were treated with the recommended dose of 4 mg/kg cabiralizumab + 3 mg/kg nivolumab Q2W, and the overall safety of these subjects is reported  independently. This study is ongoing, but enrollment is completed. Preliminary 
safety data are described below.  
[IP_ADDRESS] Phase 1a Dose Escalation (Monotherapy) 
Adverse Events  
As of 02-Jul-2018, AEs were experienced by 22 of 24 (91.7%) subjects treated in Phase 1a monotherapy 
dose-escalation cohorts. There were no Grade [ADDRESS_1197509] in  Phase 1a 
monotherapy dose-escalation cohorts.   Treatment -related AEs  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 17 of 84 Treatment -related AEs were experienced by 17 of 24 (70.8%) subjects who received cabiralizumab 
monotherapy. The most commonly reported (â‰¥ 25% of subjects) treatment -related AEs included AST 
increased (8 [33.3%] subjects), fatigue and periorbital oedema (7 [29.2%] su bjects each), and blood 
creatine phosphokinase increased (6 [25.0%] subjects). The incidence of the treatment -related AEs that 
occurred in > 10% of the subjects is listed in Table [IP_ADDRESS]-[ADDRESS_1197510] in Phase 1a monotherapy. 
 Serious Adverse Events  
Of the 24 subjects receiving cabiralizumab monotherapy, 8 (33.3%) subjects experienced at least 1 SAE. Treatment -related SAEs occurred in 2 of 24 (8.3%) subjects and included Grade 3 blood creatine 
phosphokinase increase (1 [4.2%] subject) and Grade 3 rash (1 [4.2%] subject).  Dose-limiting Toxicities  
Four DLTs were reported in the Phase 1a monotherapy arms of this study. One of the DLTs was a Grade 
[ADDRESS_1197511] increase occurred at 6 mg/kg cabiralizumab monotherapy, and the other [ADDRESS_1197512] increases occurred at 4 mg/kg cabiralizumab monotherapy. All DLTs resolved after discontinuation of study drug with no sequelae. These DLTs were all attributed to isolated increases in laboratory values ([ADDRESS_1197513] due to elevation of CK), which were expected with administration of FPA008 due to diminished clearance of ALT,  AST, CK, and LDH molecules from 
serum secondary to a reduced number of liver Kupffer cells.  Based on this information, the management 
algorithms for hepatic AEs and liver enzyme alterations have been subsequently amended to allow higher cutoffs for these laboratory values as described in sections 17.1.2 and 17.1.3. 
 Discontinuations  
A total of 3 of 24 (12.5%) subjects receiving cabiralizumab monotherapy discontinued study treatment due to a treatment -related AE, including Grade [ADDRESS_1197514] increased (2 [8.3%] subjects) and Grade 3 blood 
creatine phosphokinase inc reased (1 [4.2%] subject).   
Deaths 
A total of 14 of 24 (58.3%) subjects receiving cabiralizumab monotherapy died during the course of 
Phase 1a monotherapy. No subjects died due to an AE.  Conclusion Administration of cabiralizumab, as monotherapy, presents a tolerable safety profile. The most frequent AEs (AST and blood creatine phosphokinase increased) are aligned to the specific MOA of the molecule and can be managed by [CONTACT_859358].  
[IP_ADDRESS] Phase 1a Combination Therapy Dose Escalation 
 Adverse Events  
As of 02-Jul-2018, in the Phase 1a combination therapy dose- escalation cohorts, AEs were experienced 
by 15 of 16 (93.8%) subjects treated. In the Phase 1a combination therapy dose-escalation cohorts, 2 (12.5%) subjects had Grade 5 events, which included respi[INVESTIGATOR_859321] -related 
pneumonitis ([ADDRESS_1197515] each).  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 18 of 84 Treatment -related Adverse Events  
In the Phase 1a combination therapy dose- escalation cohorts, treatment -related AEs were experienced 
by 13 of 16 (81.3%) subjects. The most commonly reported (â‰¥ 3 subjects) treatment -related AEs 
included fatigue (8 [50%] subjects); periorbital oedema (7 [43.8%] subjects); and rash, blood creatine 
phosphokinase increased, AST increased, rash maculopapular, pruritus, and pneumonitis (3 [18.8%] subjects each). The incidence of the treatment-related AEs that occurred in > 10% of the subjects is listed in Table [IP_ADDRESS]-1 in cabiralizumab IB v6. There was 1 (25%) subject in Cohort 1aC1 that experienced a Grade [ADDRESS_1197516] developed Grade 4 pulmonary embolus, which was considered not related to study drug. Both the pneumonitis and pulmonary embolus led to respi[INVESTIGATOR_1399], which led to death.  Serious Adverse Events  
In the Phase 1a combination therapy dose-escalation cohorts, 6 of 16 (37.5%) subjects experienced at 
least 1 SAE. Treatment -related SAE s occurred in 2 of 16 (12.5%) subjects and included Grade 5 
pneumonitis (1 [6.3%] subject) and Grade 3 colitis (1 [6.3%] subject).  Dose-limiting Toxicities  
No DLTs were reported in the Phase 1a dose-escalation combination therapy arm of this study.  Discontinuations  
In the Phase 1a combination therapy dose-escalation cohorts, 2 of 16 (12.5%) subjects discontinued study treatment due to a treatment -related AE and included Grade 4 pneumonitis (1 [6.3%] subject) and 
Grade 3 colitis (1 [6.3%] subject).  Deaths 
In the Phase 1a combination therapy dose-escalation cohorts, 10 of 16 (62.5%) subjects died. One of 16 (6.3%) subjects died due to a treatment-related AE of pneumonitis.  Conclusion The combination of cabiralizumab and nivolumab, as tested in Phase 1a combination therapy dose-escalation cohorts, presents a tolerable safety profile. The most frequent AEs (periorbital oedema, blood creatine phosphokinase, and AST increased) are aligned to the specific MOA of the molecule and, as described above, can be managed by [CONTACT_859358].  
 
[IP_ADDRESS] Overall Safety of 4 mg/kg Cabiralizumab in Combination with 3 mg/kg Nivolumab Q2W 
(Cohort 1aC3 Dose Escalation, Cohorts 1b1-1b7 Dose Expansion, and Cohorts 1aE2-1aE4 Dose Exploration) 
 Adverse Events  
As of 02-Jul-2018, AEs have been experienced by 264 of 265 (99.6%) subjects treated with 4 mg/kg cabiralizumab + 3 mg/kg nivolumab Q2W across multiple cohorts.  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 19 of 84 Treatment -related Adverse Events  
Treatment -related AEs were experienced by 245 of 265 (92.5%) subjects. The most commonly reported 
(> 17% of subjects) treatment-related AEs included blood creatine phosphokinase increased (122 
[46.0%] subjects), periorbital oedema (115 [43.4%] subjects), fatigue (102 [38.5%] subjects), AST increased (100 [37.7%] subjects), ALT increased and amylase increased (51 [19.2%] subjects each), rash (50 [18.9%] subjects), and pruritus (47 [17.7%] subjects). The incidence of the treatment- related 
AEs that occurred in  > 10% of the subjects is listed in Table [IP_ADDRESS]-1. Grade 5 treatment- related AEs 
were experienced by 3 (1.1%) subjects and included acute respi[INVESTIGATOR_1399] (2 [0.8%] subjects) and respi[INVESTIGATOR_1506] (1 [0.4%] subject). These are described below. 
â€¢ A 65-year-old male Caucasian subject with NSCLC in Cohort 1b1 experienced a multifactorial 
acute respi[INVESTIGATOR_1399], with potential contributing pneumonia, pneumonitis, and chemotherapy -related pneumonitis that, despi[INVESTIGATOR_859322], led 
to death. 
â€¢ A 79-year-old male Caucasian subject with NSCLC in Cohort 1b1 experienced multiple epi[INVESTIGATOR_859323], in association with the underlying COPD and despi[INVESTIGATOR_859322], led to death. 
â€¢ A 69-year-old male Caucasian subject with NSCLC in Cohort 1b1 with a positive history of 
cardiac disease experienced multiple epi[INVESTIGATOR_859324], which led to acute respi[INVESTIGATOR_859325]. The investigator confirmed that there was no evidence of non-ST elevation myocardial infarction (NSTEMI) on ECG results and no specific test determining myocarditis. 
â€¢  
The incidence of the treatment -related AEs that occurred in > 10% of the subjects is listed in  
Table [IP_ADDRESS]-1 in cabiralizumab IB v6.  Serious Adverse Events  
A total of 134 of 265 (50.6%) subjects receiving 4 mg/kg cabiralizumab + 3 mg/kg nivolumab Q2W experienced at least 1 SAE. Treatment -related SAEs occurred in 47 of 265 (17.7%) subjects. The 
incidence of the treatment -related SAEs is listed in Table [IP_ADDRESS]-2 in cabiralizumab IB v6. 
 Discontinuations  
A total of 46 of 265 (17.4%) subjects receiving 4 mg/kg cabiralizumab + 3 mg/kg nivolumab Q2W discontinued study treatment due to an AE. A total of 43 of 265 (16.2%) subjects discontinued study treatment due to a treatment -related AE. The incidence of the treatment -related AEs is listed in Table 
[IP_ADDRESS]-3 in cabiralizumab IB v6.  Deaths 
A total of 128 of 265 (48.3%) subjects receiving 4 mg/kg cabiralizumab + 3 mg/kg nivolumab Q2W died during the course of the study. A total of 17 of 265 (6.4%) subjects died due to an AE, and treatment -related Grade 5 AEs were experienced by 3 of 265 (1.1%) subjects and included acute 
respi[INVESTIGATOR_1399] (2 [0.8%] subjects) and respi[INVESTIGATOR_1506] (1 [0.4%] subject).  Conclusion The combination of 4 mg/kg cabiralizumab + 3 mg/kg nivolumab Q2W appears to be well tolerated. The most frequent treatment-related AEs (blood creatine phosphokinase increased, periorbital oedema, fatigue, AST increased, amylase increased, and ALT increased) are aligned to the MOA of 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 20 of 84 cabiralizumab or nivolumab and can be managed by [CONTACT_859359]. Of note, despi[INVESTIGATOR_859326]- related AEs (92.5%), only a 
minority (16.2%) of the subjects treated with 4 mg/kg cabiralizumab + 3 mg/kg nivolumab Q2W discontinued the treatment due to a treatment- related AE.  
1.6.[ADDRESS_1197517] of anti-CSF1R antibodies on the Kupffer cell in the liver that results in a depletion of these cells. Depletion of Kupffer cells allows the enzymes, which are released following normally occurring liver cell turnover, to enter circulation (where they are measured by [CONTACT_859360]) rather than being absorbed by [CONTACT_737451]. Elevated liver enzymes, thus, represent a PD marker rather than a 
safety signal. The observed elevations were asymptomatic not permanent and not associated with clinical sequelae. Similar effects have been observed across other CSF1R targeted agents (see cabiralizumab IB for additional details). The data wi th cabiralizumab and with other agents in the class 
suggest that the observed serum enzyme elevations do not compromise the safety profile of cabiralizumab and therefore support modification of the safety monitoring criteria.   Serum Enzyme Elevations in Cabiralizumab See above sections for descriptions of serum enzyme elvations in various clinical trials . Based on phase 
1a data from FPA008 003, the management algorithms for hepatic AEs and liver enzyme alterations have been subsequently amended to allow higher cutoffs for serum hepatic enzyme elevations as described in sections 17.1.[ADDRESS_1197518] been used to re-evaluate the safety of 4 mg/kg cabiralizumab monotherapy (7 subjects) and 4 mg/kg cabiralizumab in combination with 3 mg/kg nivolumab (3 subjects). No DLTs were reported in subjects treated at these doses under the revised algorithms.  Since then, approximately [ADDRESS_1197519] been treated with 4 mg/kg cabiralizumab in combination with 3 mg/kg nivolumab using the new management algorithms for hepati c AE and 
liver enzyme, and no Grade [ADDRESS_1197520]. To rule 
out any potential hepatic injury in relation to elevated transaminases, additional monitoring following 
the DILI Guidance from FDA
 will be perfor med for bilirubin, INR, and ALT/AST. In the case of 
elevated CK, additional assessments will be performed for CK isoenzymes (CK- MM, CK-MB, and CK-
BB) and troponins (I or T). The investigator should notify the Sponsor of increased serum levels above specific cutoffs, but below those that would trigger drug modification or discontinuation. Additional 
monitoring of clinical signs and symptoms known to be associated with hepatic damage, per the FDA DILI Guidance, is recommended. These additional measures should be followed as per the guidance in section 17.1. 
 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 21 of 84 Rationale for starting dose  
The rationale for starting dose of combination therapy is based upon the dose escalation and expansion 
phases of FPA008-003 as in the Clinical Summary above. Since PPK and exposure response analyses 
support the use of 240 mg Q2W dosing in addition to the 3 mg/kg Q2W regimen for nivolumab (see 
Section 1.5), flat dosing of nivolumab at [ADDRESS_1197521] on the PK of cabiralizumab.  
1.7 Rationale 
The tumor microenvironment, composed of non- cancer cells and stroma, is recognized as a major factor 
influencing the growth of tumor cells. Tumor- associated macrophages (TAMs) are particularly abundant 
in the tumor microenvironment and are thought to play a key role in promoting tumor growth. TAMs 
can promote angiogenesis (blood vessel formation in tumors), tumor survival, and metastasis, and may confer resistance to current therapi[INVESTIGATOR_014]. TAMs are also immunosuppressive and through the release of soluble factors and cell surface T cell checkpoint inhibitors can suppress anti-tumor T cell responses [41]. In the majority of tumors increased numbers of TAMs corre late with poor clinical outcome [42], 
supporting TAMs as an attractive therapeutic target. Immunosuppressive TAMs are dependent on CSF1 for survival; a drug that inhibits CSF1R could limit the influence of TAMs on the tumor microenvironment and could be complementary and augment current cancer therapi[INVESTIGATOR_014], e.g., checkpoint-based immunotherapi[INVESTIGATOR_859327]1 or CTLA4 pathways.   Targeting the CSF1R pathway with antibodies or small molecule inhibitors has been shown to be effective in mouse tumor models. In a MC38 colon adenocarcinoma model in syngenei c mice, an anti -
CSF1R blocking antibody resulted in a significant reduction in TAMs, which was accompanied by a positive shift of the CD8 to CD4 ratio toward cytotoxic CD8 T cells[ 30]. This was associated with a 
decrease in FoxP3+ regulatory T cells. These data suggest that other immune effector cells were indirectly influenced by [CONTACT_38247]1R blockade. In a mouse proneural glioblastoma multiform model, small molecule inhibition of CSF1R significantly increased survival, and established tumors regressed[ 29]. In 
this model, TAMs were not depleted, but in the presence of CSF1R inhibition, were pushed to a more proinflammatory phenotype.  In an orthotopic pancreatic ductal adenocarcinoma (PDAC) model, CSF1R pathway blockade with a small molecule or an anti -CSF1 antibody selectively decreased immunosuppressive TAMs, resulting in 
decreased immunosuppression, and enabled the remaining pro-inflammatory TAMs to support antigen presentation and bolster the anti-tumor T cell response[ 44]. This in turn led to an increased interferon 
response that upregulated T cell checkpoint inhibitors including PD-L1 on tumor cells. This counter regulation served to limit the anti- tumor T cell response through engagement of the T cell inhibitor PD1. 
Importantly, anti- PD1or anti -CTLA4 treatment was able to overcome the PDL1 -mediated inhibition. 
Anti-PD1 or anti-CTLA4 as single agents showed limited efficacy in restraining PDAC tumor growth 
but combining these agents with CSF1R blockade potently elicited tumor regression even in large established tumors. These data suggest that reprogramming the TAM compartment in tumors by [CONTACT_38247]1R blockade could improve the efficacy of checkpoint- based immu notherapi[INVESTIGATOR_859328]- PD1 
blocking antibody. 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 22 of 84  
In a recent clinical study, RG7155 an anti-CSF1R blocking antibody was tested in patients with various types of solid tumors and was shown to substantially reduce CSF1R+ and CD163+ macrophages in tumors[30]. Similar to what was seen in the mouse model, reduction of TAMs was associated with an 
increase in t he CD8 to CD4 T cell ratio, suggesting that TAM reduction leads to an increased CD8 
cytotoxic T cell response in humans.  Together these data suggest that targeting CSF1R via BMS -[ADDRESS_1197522] 
aberrant expression of CSF1R which can lead to tumor growth (reviewed in section 1.3). Additionally, 
LAMs, which are dependent upon CSF1 for survival, have a well-established role in tumor progression in PTCL (reviewed in section 1.3). Previous clinical trials have shown significant responses to 
checkpoint blockade in patients with PTCL (reviewed in section 1.2). Therefore, we  propose a 
multicenter, phase II study of nivolumab and the antagonistic CSF-1R monoclonal antibody 
cabiralizumab ( BMS-986227) in patients with relapsed/refractory PTCL.   
2. STUDY OBJECTIVES AND ENDPOINTS  
2.1 Objectives  
2.1.1 Primary Objectives 
1) To estimate objective response (OR) rate (ORR) to nivolumab and cabiralizumab in 
relapsed/refractory peripheral T cell lymphoma (PTCL) by [CONTACT_859346] 4 months 
2) To estimate complete  response (C R) rate (CRR) to nivolumab and cabiralizumab in 
relapsed/refractory peripheral T cell lymphoma (PTCL) by [CONTACT_859346] 4 months 
2.1.2 Secondary Objectives  
1) To estimate ORR and CRR of this combination by [CONTACT_415580] 2014 criteria at 4 months.  
2) To estimate the best OR  (including PR and CR) at any time on trial by [CONTACT_859361] 
3) To estimate progression free survival (PFS) 
4) To estimate disease control rate (DCR)  
5) To estimate duration of response (DOR)  
6) To estimate time to next treatment (TNT)  
7) To evaluate the safety and tolerability of the combination of cabiralizumab and nivolumab. 
2.1.3 Correlative/Exploratory Objectives  
1) To examine the role of lymphoma associated macrophage (LAM), regulatory T cell (Treg), and cytotoxic T lymphocyte (CTL) densities (before and during treatment) as pharmacodynamic and prognostic biomarkers.  
2) To examine the role of PD-L1 and CSF-1R expression as pharmacodynamic and prognostic biomarkers. 
3) To examine the abundance of â€œexhaustedâ€ T cells in the peripheral blood as a pharmacodynamic and prognostic biomarker. 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 23 of 84 4) To evaluate the feasibility and utility of minimal residual disease (MRD) monitoring throughout 
treatment as a ph armacodynamic and prognostic biomarker. 
5) To evaluate the role of myeloid derived suppressor cells (MDSC) as a pharmacodynamic and prognostic biomarker. 
6) To biobank diagnostic biopsy specimens and other biologic specimens or blood for future correlative studies.  
2.2 Endpoints  
2.2.1 Primary Endpoint s 
1. Overall res ponse, as determined by [CONTACT_859362] (Section 17.5), within [ADDRESS_1197523] cycle 
2. Complete response, as determined by [CONTACT_859362] (Section 17.5), within [ADDRESS_1197524] cycle  
2.2.2 Secondary Endpoints  
1. Overall response and complete response by [CONTACT_165219] (Section 17.6) at 4 months.  
2. Progression-Free Survival ( PFS) as defined in section 9.3.4 
3. Duration of Overall Response ( DOR), as defined in section 9.3.6 
4. Time to Next Treatment ( TNT), as defined in section 9.3.7. 
5. Adverse events (AEs) using NCI Common Terminology Criteria for Adverse Events (CTCAE) 
version 5. 
3. ELIGIBILITY CRITERIA  
3.[ADDRESS_1197525] meet all of the following applicable inc lusion criteria to participate in this study: 
 
1. Written informed consent for clinical trial enrollment and mandatory consent for any biopsies as well as HIPAA authorization for release of personal health information. NOTE:   HIPAA 
authorization may be included in the informed consent or obtained separately. 
2. Age â‰¥ 18 years at the time of consent.  
3. ECOG Performance Status of  0-2. 
4. Histological confirmation of peripheral T- cell lymphoma (PTCL)  with measurable disease on 
imaging. Adult T- cell leukemia/lymphoma (ATLL)  are excluded . 
5. Documented disease progression after receiving at leas t two prior therapeutic regimen including 
brentuximab vedotin in patients with CD30 positive disease (defined as >10% CD30 positive cells).  
6. Prior cancer treatment must be completed at least [ADDRESS_1197526] recovered from all reversible acute toxic effects of the regimen (other than alopecia) to â‰¤ grade 1 or baseline. Systemic steroids at a dose less than the equivalent of 10 mg/day of prednisone and inhaled, nasal, and topi[INVESTIGATOR_12977]. A drenal replacement steroid 
doses > 10 mg daily prednisone equivalent in the absence of active autoimmune disease are  
permitted. Treatment with a short course of steroids (< 5 days) up to 7 days prior to study 
registration  is permitted.  Intermittent dexamethasone for the treatment of nausea/emesis is also 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 24 of 84 permitted.  
7. Demonstrate adequate organ function as defined in the table below; all screening labs to be 
obtained within 28 days prior to registration .  
System Laboratory Value  
Hematolog ical 
Absolute Neutrophil Count (ANC)  â‰¥ 1000/mm3 
Platelets (Plt ) â‰¥ 75,000/ mm3 
Renal 
Calculated creatinine clearance  â‰¥ 30 cc/min using the Cockcroft -Gault 
formula 
Serum creatinine  â‰¤1.[ADDRESS_1197527]  
Hepatic 
Bilirubin â‰¤ 1.5 Ã— upper limit of no rmal (ULN)  (except 
patients with Gilbert's syndrome, who must 
have total bilirubin <3 mg/dL)  
Aspartate aminotransferase  (AST) â‰¤ 1.5 Ã— ULN or â‰¤ 2 Ã— ULN in the presence 
of known or suspected hepatic involvement  
Alanine aminotransferase  (ALT) â‰¤ 1.5 Ã— ULN or â‰¤ 2 Ã— ULN in the presence 
of known or suspected hepatic involvement  
 
8. Women of childbearing potential (WOCBP)  must have a negat ive serum or urine pregnancy test 
(minimum sensitivity of 25 IU/L or equivalent units of human chorionic gonadotropin) 
performed at screening and within [ADDRESS_1197528] use any contraceptive method with a failure rate of less than 1% per year. Men receiving study drugs and who are sexually active with 
WOCBP will be instructed to adhere to contraception for a period of [ADDRESS_1197529] to 
understand and comply with study procedures for the entire length of the study 
3.2 Exclusion Criteria  
Subjects meeting any of the criteria below may not participate in the study: 
 
1. PTCL histology consistent with ATLL. 
2. A history of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigatorâ€™s opi[INVESTIGATOR_1649], could affect the conduct of the study. 
3. Active infection requiring systemic therapy 
4. Recent (<100 days) autologous stem cell transplant, or previous allogeneic stem cell transplant. 
5. Known positive test for HIV. NOTE: HIV s creening is not required. 
6. History of any chronic hepatitis as evidenced by [CONTACT_716]: 
a) Positive test for hepatitis B surface antigen  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 25 of 84 b) Positive test for qualitative hepatitis C viral load (by [CONTACT_940] [PCR]).  
NOTE: Participants with positive hepatitis C antibody and negative quantitative hepatitis C by 
[CONTACT_859363]. History of resolved hepatitis A virus infection is not an exclusion criterion. 
7. Pregnant or breastfeeding. NOTE:  breast milk cannot be stored for future use while the mother is 
being treated on study. 
8. Previous malignancies (except non- melanoma skin cancers and in situ bladder, gastric, 
colorectal, endometrial, cervical/dysplasia, melanoma, or breast cancers) unless complete 
remission was achieved at least 2 years prior to study entry and no additional therapy is required during the study period. 
9. Prior treatment with  cabiralizumab.   
10. Prior treatment with nivolumab or other medications within the checkpoint blockade family. 
11. Any unregulated nutritional or herbal supplement or recreational drug within 2 weeks prior to registration  which, in the opi[INVESTIGATOR_103160], has the potential to cause hepatic 
injury. 
12. Concomitant use of statins for treatment of hypercholesterolemia . Statins are allowed only if the 
patient is on a stable dose for over 3 months prior to study registration  and is in a stable status 
without CK elevations . 
13. Non-oncology vaccine therapi[INVESTIGATOR_754399] (e.g., human papi[INVESTIGATOR_859329]) within 4 weeks of study registration . The inactivated seasonal influenza vaccine 
can be given to patients before treatment and while on therapy without restriction. Influenza vaccines containing live virus or other clinically indicated vaccinations for infectious diseases (i.e., pneumovax, varicella, etc.) may be permitted, but must be discussed with the sponsor investigator and may require a study drug washout period before and after administration of vaccine. 
14. Known history of sensitivity to infusions containing Tween 20 (polysorbate 20) and Tween 80 (polysorbate 80) 
15. History of allergy to any components of cabiralizumab or nivolumab 
16. Active, known, or suspected autoimmune disease.  NOTE: Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to 
autoimmune condition only requiring hormone replacement, euthyroid participants with a history of Graveâ€™s disease (pa rticipants with suspected autoimmune thyroid disorders must be negative 
for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study treatment), psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll after discussing with the sponsor investigator. 
17. Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment -related pulmonary toxicity. 
18. Current or history of clinically significant muscle disorders (e.g., myositis), recent unresolved muscle injury, or any condition known to elevate serum CK levels. 
19. Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following: a) Myocardial infarction or stroke/transient ischemic attack within the past 6 months  
b) Uncontrolled angina within the past 3 months 
c) Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes) 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 26 of 84 d) History of other clinically significant heart disease ( e.g., cardiomyopathy (impaired LVEF) , 
congestive heart failure with [LOCATION_001] Heart Association functional classification III to IV, 
pericarditis, significant pericardial effusion, or myocarditis) 
e) Cardiovascular disease-related requirement for daily supplemental oxygen therapy. 
 
4. SUBJECT REGISTRATION  
All subjects must be registered through Big T en CRC Administrative Headquartersâ€™  electronic data 
capture (EDC) system. A subject is considered registered when an â€œOn Studyâ€ date is entered into the 
EDC system.   
 Subjects must be registered prior to starting protocol therapy.  
5. TREATMENT PLAN  
This is a single arm phas e II study. Please refer to study schema for overview. Therapy will consist of 
nivolumab 240 mg IV given over 30 minutes (-5/ +15 minutes) followed by 30 minutes (-5/ +15 
minutes) of rest followed by [CONTACT_754437] 4mg/kg IV over 30 minutes (-5/ +15 minutes) . Treatment 
will be given on day 1 of every 14 day cycle. Participants may continue on treatment until withdrawal of 
consent, death, or initiation of another anti- cancer treatment.  
 If a trial participant achieves a complete response (CR) per criteria outlined in section 9, they will 
discontinue study therapy 6 months after confirmed and persistent CR (repeat evaluations required prior to therapy discontinuation as outlined in section 7). This will be followed by a period of observation. Patient will have a physical exam and labs (CBC, CMP, mineral panel, creatine kinase, LDH, amylase, lipase, TSH, free T4, and cortisol) every [ADDRESS_1197530] will be obtained every 6 months; study labs including PBMC, whole blood, and serum will be collected with every imaging evaluation per the schedule of events in section 7. Observation will continue for a period of 2 years; i f at 
any point during the 2 years of observation the patient relapses, they may resume therapy at the time o f 
disease progression. Upon restarting therapy, the schedule of events will resume as if starting at C1D1 of 
therapy (ie PET every 4 cycles, every 2 week office visits with applicable labs, etc).  
 
Study treatments  
Product Description / 
Class and Dosage Form  Potency/ Route of 
Administration  Blinded or 
Open Label  Packaging  Storage 
Conditions  
Nivolumab  
(BMS-936558-01) 
Solution for Injection  100 mg 
(10 mg/mL)  Open label  Vial Refer to the label 
on container  
Cabiralizumab  
(BMS-986227) 
Solution for Injection 100 mg 
(20 mg/mL)  Open label  Vial Refer to the label 
on container  
 
5.1 Pre-medication and Hydration 
In general, the use of pre-medications with nivolumab and cabiralizumab is not anticipated. P re-
medications including anti emetics are permitted if needed. Guidelines for premedication with 
subsequent cycles to prevent recurrence of infusion reaction are available in section  6.2.  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 27 of 84 5.2 Nivolumab plus Cabiralizumab Administration  
Drug Dose Route Schedule1 Cycle 
Length 
Nivolumab 240 mg Intravenously (IV) over 30 minutes  
(-5/ +15 min) Day 1 
14 days 
Cabiralizumab  4 mg/kg2 IV over 30 minutes (-5/ +15 min) 
beginning 30 minutes (-5/ +15 min) 
after completion of nivolumab Day 1 
1 A window of Â± [ADDRESS_1197531]â€™s chart and electronic case report 
forms (eCRFs). 
2 Cabiralizumab dose should be recalculated if Day 1 weight changes by >10%.  
5.[ADDRESS_1197532]â€™s welfare may be administered at the 
discretion of the investigator in keepi[INVESTIGATOR_859330] 5.4. 
5.3.2 Prohibited Concomitant Medications 
Drug-drug interactions are not anticipated with the use of either nivolumab or cabiralizumab (see Drug 
Interactions in sections 1.5 and 1.6)  The following medications are prohibited during the study (unless utilized to treat a drug- related AE or 
specified in the eligibility section) . Medications taken  within [ADDRESS_1197533] of prohibited mediacations.  
1) Immunosuppressive agents or immunosuppressive doses of systemic corticosteroids 
2) Vaccines except as noted in  Section 3.2.15. 
3) Other anti -neoplastic therapi[INVESTIGATOR_754411], immunotherapy, extensive non- palliative 
radiation therapy, standard treatments, or investigational agents or devices. 
4) Systemic steroids at a dose greater than the equivalent of 10 mg/day of prednisone except as  needed 
for immune related adverse events as outlined in section 17.1. Inhaled, nasal, and topi[INVESTIGATOR_12977]. Intermitte nt dexamethasone for the treatment of nausea/emesis  or infusion reactions is 
also permitted.  
5) Concurrent use of hormones for noncancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable.  
5.[ADDRESS_1197534]. Women of childbearing potential are defined as any female who has 
experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as [ADDRESS_1197535] a documented serum follicle stimulating hormone (FSH) level higher than 40 mIU/mL.  Men who are sexually active with WOCBP must use any contraceptive method with a f ailure rate of less 
than 1% per year . Men receiving study drug and who are sexually active with WOCBP will be instructed 
to adhere to contraception for a period of [ADDRESS_1197536].  Subjects should be informed that taking the study medication may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study. To participate in the study, they must adhere to the contraception requirements described above for the duration of the study and during the follow -up 
period. If there is any question that a subject will not reliably comply with the requirements for 
contraception, that subject should not be entered into the study. 
[IP_ADDRESS] Highly Effective Methods of Contraception 
â€¢ Male condoms with spermicide 
â€¢ Hormonal methods of contraception including combined oral contraceptive pi[INVESTIGATOR_3353], vaginal 
ring, injectables, implants and intrauterine devices (IUDs) such as Mirena
ï›š by [CONTACT_52230]â€™s WOCBP partner . Female partners of male subjects participating 
in the study may use hormone based contraceptives as one of the acceptable methods of 
contraception since they will not be receiving study drug 
â€¢ Nonhormonal IUDs, such as ParaGardï›š 
â€¢ Tubal ligation  
â€¢ Vasectomy  
â€¢ Complete Abstinence*  
*Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs. Subjects who choose complete abstinence are not required to use a second method of contrace ption. Acceptable alternate 
methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence. 
[IP_ADDRESS] Less Effective Methods of Contraception  
â€¢ Diaphragm with spermicide 
â€¢ Cervical cap with spermicide  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 29 of 84 â€¢ Vaginal sponge 
â€¢ Male Condom without spermicide  
â€¢ Progestin only pi[INVESTIGATOR_114547]â€™s WOCBP partner  
â€¢ Female Condom*. 
* A male and female condom must not be used together 
6. TOXICITIES AND DOSE DELAYS/DOSE MODIFICATIONS  
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5 will be used to grade adverse 
events.  
 Subjects enrolled in this study will be evaluated clinically and with standard laboratory tests before and 
at regular intervals during their participation in this study as speci fied in Study Calendar & Evaluations. 
 Subjects will be evaluated for adverse events (all grades), serious adverse events, and adverse events 
requiring study drug interruption or discontinuation as specified in Study Calendar & Evaluations.    Please see section 17.1 for management of toxicities that may arise during the course of treatment. 
6.1 Dose Delays/Dose Modifications 
Guidelines for delaying, restarting, or discontinuing therapy for various toxicities is included in sections 17.1 and 17.2. Dose modifications  are not permitted for this protocol , except if Day 1 weight change by 
>10% necessitates a change in the dosing of cabiralizumab . If therapy is delayed, then next infusion date 
will be considered day 1 of the subsequent cycle. 
 In addition to sections 17.1 and 17.2, please see below for dose delays related to hematologic toxicity:  
â€¢ For Grade 1 -2 (neutrophils <LLN to 1,000/ÂµL, hemoglobin <LLN to 8 g/dL, platelets <LLN to 
50,000/ÂµL) 
o Rule out alternative causes  
o Continue cabiralizumab  and nivolumab  therapy 
o Monitor CBC per schedule of events 
o If worsens, treat as grade 3 -4 toxicity  
 
â€¢ For Grade 3 -4 (neutrophils < 1,000/ÂµL, hemoglobin < 8 g/dL, platelets < 50,000/ÂµL 
o Rule out alternative causes  
o Delay cabiralizumab and nivolumab therapy. If the AE requiring dose delay was due to one of the study drugs, the non-offending drug may be continued, taking into account the safety and clinical benefit to the patient.  
o Treat autoimmune cy topenias per standard institutional guidelines (examples below): 
ï‚§ Immune thrombocyoptenia may be treated with steroids, immune globulin, or rituximab  
ï‚§ Immune mediated hemolytic anemia may be treated with steroids, immune globulin, or rituximab 
ï‚§ Immune mediate d neutropenia may be treated with steroids, colony stimulating 
factors, or immune globulin 
o If improves to < grade 3: 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 30 of 84 ï‚§ May resume cabiralizumab and nivolumab therapy per protocol 
o If does not improve or worsens: 
ï‚§ Discontinue therapy. If the AE requiring discontinuation was due to one of the 
study drugs, the non-offending drug may be continued, if there is timely 
resolution of AE and clinical benefit is shown by [CONTACT_4676]. 
ï‚§ Continue to treat immune mediated cytopenias per standard algorithms 
ï‚§ Continue follow up until resolution 
o Grade 3 drug- related thrombocytopenia associated with grade â‰¥ [ADDRESS_1197537], followed by [CONTACT_859364] 30 -minute infusion. It may be unclear if an infusion reaction is due to cabiralizumab, 
nivolumab, or to both study drugs. Therefore, one set of treatment recommendations (based on the most conservative treatments for infusion reactions due to either study drug) is provided below and may be modified based on clinical judgment, local treatment standards and guidelines, and/or specific symptoms, as appropriate.  For Grade 1 symptoms : Mild reaction (eg, localize d cutaneous reactions including mild pruritus, 
flushing, and rash), requires infusion rate to be decreased; intervention may be indicated. 
â€¢ Decrease the rate of the study drug infusion until recovery from symptoms. 
â€¢ Remain at bedside and monitor the patientâ€™ s vital signs until resolution of symptoms.  
â€¢ Diphenhydramine 50 mg may be administered at the discretion of the treating physician. 
â€¢ When symptoms resolve, restart the infusion at the original infusion rate. 
â€¢ If a patient has an infusion reaction with nivolumab, cabiralizumab can be given (without 
prophylactic medications) if the infusion reaction resolves within 3 hours. For scheduling 
purposes, the cabiralizumab infusion may be given the next day. Prophylactic pre-infusion medications should be given prior to all subsequent nivolumab infusions. 
â€¢ If a patient has an infusion reaction with cabiralizumab, prophylactic pre-infusion medications should be given prior to all subsequent cabiralizumab and nivolumab infusions. 
â€¢ The following prophylactic pre-infusion medications are recommended prior to future infusions of cabiralizumab and nivolumab: diphenhydramine 50 mg (or equivalent) and/or paracetamol (acetaminophen) [ADDRESS_1197538] 30 minutes before additional study drug administrations.  
 For Grad e 2 symptoms : Moderate reaction (ie, any symptom not listed above [mild symptoms] or 
below [severe symptoms] such as generalized pruritus, flushing, rash, dyspnea, and hypotension with systolic blood pressure >80 mmHg), requires infusion interruption but responds promptly to 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 31 of 84 symptomatic treatment (eg, antihistamines, nonsteroidal anti-inflammatory drugs, narcotics, 
corticosteroids, and IV fluids); prophylactic pre-infusion medications indicated for â‰¥24 hours. 
â€¢ Interrupt the study drug infusion. 
â€¢ Begin an IV infusion of normal saline and treat the patient with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol (acetaminophen) 325 mg to 1000 mg. 
â€¢ Remain at bedside and monitor the patientâ€™s vital signs until resolution of symptoms. 
â€¢ Corticosteroid therapy may be administered at the discretion of the treating physician. 
â€¢ When symptoms resolve, restart the infusion at 50% of the original infusion rate; if no further 
complications ensue after 30 minutes, the rate may be increased to 100% of the original infusion rate. 
â€¢ Monitor the patient closely. If symptoms recur, immediately discontinue the infusion; no further study drug will be administered at that visit. Administer diphenhydramine 50 mg IV, and remain 
at bedside and monitor the patient until resolution of symptoms. 
â€¢ If a patient has  an infusion reaction with nivolumab infusion, cabiralizumab infusion can be 
given (without prophylactic medications) if the infusion reaction resolves within 3 hours. For scheduling purposes, the cabiralizumab infusion may be given the next day. Prophylactic pre -
infusion medications should be given prior to all subsequent nivolumab infusions. 
â€¢ If a patient has an infusion reaction with cabiralizumab, prophylactic pre-infusion medications 
should be given prior to all subsequent cabiralizumab and nivolumab infusions. 
â€¢ The following prophylactic pre-infusion medications are recommended prior to future infusions of cabiralizumab  and nivolumab: diphenhydramine 50 mg (or equivalent) and/or paracetamol 
(acetaminophen) [ADDRESS_1197539] 30 minutes  before 
additional study drug administrations. If necessary, corticosteroids (up to 25 mg of SoluCortef or equivalent) may be used. 
â€¢ The amount of study drug infused must be recorded. 
 For Grade 3 or Grade 4 symptoms : Severe reaction such as bronchospasm, generalized urticaria, 
systolic blood pressure <80 mmHg, or angioedema; Grade 3 symptoms including prolonged symptoms, 
which require 6 or more hours to respond to symptomatic medication and/or discontinuation of infusion; 
recurrence of symptoms following initial improvement; hospi[INVESTIGATOR_14138], such as renal impairment, pulmonary infiltrates; Grade 4: life -threatening; pressor or 
ventilation support indicated. 
â€¢ Immediately  discontinue the study drug infusion. No further study drug will be administered. 
The amount of study drug infused must be recorded on the CRF. 
â€¢ Begin an IV infusion of normal saline and treat the patient as follows: Recommend bronchodilators, epi[INVESTIGATOR_238] 0.2 mg to 1.0 mg of a 1:1,000 solution for subcutaneous administration or 0.1 mg to 0.25 mg of a 1:10,000 solution injected slowly for IV administration, and/or diphenhydramine 50 mg IV with methylprednisolone 100 mg IV (or equivalent), as needed. 
â€¢ Remain at bedside and monitor the patientâ€™s vital signs until recovery from symptoms. 
â€¢ The patient should be monitored until the investigator is comfortable that the symptoms will not 
recur. 
â€¢ Investigators should follow their institutional guidelines for t he treatment of anaphylaxis.  
 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 32 of 84 In the case of late -occurring hypersensitivity symptoms (eg, appearance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral antihistamine or 
corticosteroids). 
6.3 Protocol Therapy Discontinuation 
The reason for discontinuation of protocol therapy will be documented on the electronic case report 
form (eCRF).  Instructions for management and discountinuation of therapy for common or expected AEs is included in sections 17.1 and 17.2. Please refer to these sections for instructions regarding therapy discontinuation for diarrhea/colitis, hepatic toxicity, renal toxicity, pulmonary toxicity, endocrinopathy toxicity, skin toxicity, neurologic toxicity, periorbital edema, uveitis, and CK or LDH elevation. In addition, criteria for discontinuation due to hematologic toxicity are outlined in section  6.1. In addition 
to these, a subject will also be discontinued from protocol therapy and followed up per protocol under 
the circumstances  outlined below.  
 
â€¢ Documented disease progression 
â€¢ The treating physician thinks a change of therapy would be in the best interest of the subject 
â€¢ The subject requests to discontinue protocol therapy, whether due to unacceptable toxicity or for 
other reasons o If a subject decides to prematurely discontinue prot ocol therapy (â€œrefuses treatmentâ€), the 
subject should be asked if he or she may still be contact[CONTACT_353196]. The outcome of that discussion should be documented in both the medical records and in the eCRF. 
â€¢ A female subject b ecomes pregnant  
â€¢ Any Grade 3 or higher infusion-related reactions and hypersensitivity requiring discontinuation. 
Any re-initiation of therapy in this circumstance would require consultation with the Sponsorâ€™s 
Medical Monitor or designee. 
â€¢ Isolated Grade 3 electrolyte imbalances/abnormalities that are not associated with clinical sequelae  
â€¢ Any Grade 4 drug-related AE or laboratory abnormality not addressed in sections 6.1, 17.1, or 17.2, except for the following events which do not require discontinuation: o Refractory hematologic toxicities as in section 6.1 
o Isolated Grade 4 amylase or lip ase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis. The Sponsorâ€™s Medical Monitor or designee should be consulted for Grade 4 amylase or lipase abnormalities.  
o Isolated Grade 4 electrolyte imbalances/abnormali ties that are not associated with clinical 
sequelae and are corrected with supplementation/appropriate management within 72 hours of their onset 
o Grade 4 drug-related endocrinopathy AEs, such as adrenal insufficiency, adrenocorticotropic hormone deficiency, hyper- or hypothyroidism, or glucose intolerance, which resolve or are adequately controlled with physiologic hormone replacement (corticosteroids, thyroid hormones) or glucose-controlling agents, respectively, may not require discontinuation after discussion with and approval from the Sponsorâ€™s Medical Monitor or designee. 
â€¢ If CK is elevated, CK subsets, EKG and troponin will be obtained as outlined in section 17.2. If troponin is elevated above institutional upper limit of normal, evaluation of EF will be performed.  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 33 of 84 o If Grade â‰¥2 myocarditis is confirmed per AHA diagnostic criteria (Bozkurt, Circulation. 2016 
Dec 6;134(23):e579-e646.), patient will be taken off protocol.  
â€¢ Any event that leads to delay in dosing lasting > 6 weeks from the previous dose requires  
discontinuation, with the following exceptions: o Therapy discontinuation due to achievement of a CR as outlined in Section 5 
o Dosing delays to manage drug- related AEs are allowed. Prior to re- initiating treatment in a 
participant with a dosing delay lasting > 6 weeks from the previous dose, the Sponsorâ€™s Medical Monitor or designee must be consulted. Tumor assessments should continue as per-protocol even if dosing is delayed. Periodic study visits to assess safety and laboratory studies should also continue per protocol, or more frequently if clinically indicated during such dosing delays or per the Investigatorâ€™s discretion. 
o Dosing delays lasting > 6 weeks from the previous dose that occur for non-drug- related reasons 
may be allowed if approved by [CONTACT_1034]â€™s Medical Monitor or designee. Prior to re- initiating 
treatment in a participant with a dosing delay lasting > 6 weeks, the Sponsorâ€™s Medical Monitor must be consulted. Tumor assessments should continue per protocol even if dosing is delayed. Periodic study visits to assess safety and laboratory studies should also continue per-protocol or more frequently  if clinically indicated during such dosing delays or per the investigatorâ€™s 
discretion. 
â€¢ Any AE, laboratory abnormality, or intercurrent illness which, in the opi[INVESTIGATOR_871], presents a substantial clinical risk to the participant with continued cabiralizumab and/or nivolumab dosing 
â€¢ If the causality of the AE requiring discontinuation is confirmed to be due to one of the study drugs in the combination therapy, the other drug(s) may be continued per-protocol schedule under the following scenarios: o Timely resolution of the AE based on the treatment modification table  
o Clinical benefit is shown by [CONTACT_754442]. 
6.[ADDRESS_1197540] decides to withdraw from the study (and not just from protocol therapy) all efforts should be 
made to complete the final study assessments. The site study team should contact [CONTACT_859365] a clinic  visit to determine  the reason for the study withdrawal. If the reason for 
withdrawal  is an adverse event, it will be recorded on the eCRF  and reported. 
Big Ten Cancer Research Consortium      Clinical Study Protocol  
         BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 34 of 84 7. STUDY CALENDAR & EVALUATIONS  
 
Cycle= [ADDRESS_1197541] CR10/ 
observation  Safety 
follow up  Long-term 
Follow up4 
-28 
days 1 2 3 4 5+ [ADDRESS_1197542] 
dose Every 3 
months  
(Â±14 days) D11 D1 D1 D1 D1 
REQUIRED  ASSESSMENTS           
Review of eligibility criteria,  Informed Consent   X         
Medical History16, Diagnosis and Staging (Lugano5) X         
Physical Exam, V ital Signs6, ECOG PS7 X X X X X X17 Q3 mos X  
EKG X         
AEs & Concomitant Medications  X X X X X X  D30, 1003 X3 
LABORATORY ASSESSMENTS           
Complete blood cell co unt with diff erential (CBC)15 X X X X X X Q3 mos X  
Comprehensive metabolic p rofile (CMP)8, 15 X X X X X X Q3 mos X  
Mineral panel (phosphorus, magnesium, calcium) [ADDRESS_1197543] (serum or urine)  in WOCBP9 X X  X  C5, 7, etc9    
DISEASE ASSESSMENT           
PET/CT Scan10 -30d     X10 Q6 mos   
Bone marrow aspi[INVESTIGATOR_12752] (unilateral)11 X     X X11   
TREATMENT EXPOSURE           
Nivolumab 240 mg IV   X X X X X    
Cabiralizumab 4 mg/kg IV   X X X X X    
CORRELATIVE STUDIES (SPECIMEN COLLECTION)          
Fresh tumor tissue  biopsy12 X     C513, @PR13    
Whole blood for somatic baseline   X        
PBMCs and plasma14  X  X  C5,@imaging  @imaging  X  
BANKING SAMPLES (SPECIMEN COLLECTION)          
Whole Blood14  X  X  C5, @imaging @imaging  X  
Serum  X  X  C5, @imaging @imaging  X  
Tumor Tissue12 X     C513, @PR13    
FOLLOW -UP          
Disease progression          X 
Big Ten Cancer Research Consortium      Clinical Study Protocol  
         BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 35 of 84 Key to Footnotes  
1If screening (baseline) labs were performed within 7 days of C1D1 of treatment, these do not need to be repeated.   
2A window of 3 days will be applied to all treatment study visits; for safety follow-up visit, tumor imaging, bone marrow biopsy, and lymph node 
biopsy, a 7-day window will apply. 
3A safety follow-up visit will  occur 30 days (Â±7 days) after the last dose of treatmen t. Subjects who have an ongoing â‰¥ grade 2 or serious AE 
(SAE) at this visit will continue to be followed until the AE resolves to â‰¤ Grade 1 or baseline, is deemed clinically insignificant, and/or until a new 
anti-cancer treatment starts, whichever is earlier.  AEs will be collected for 100 days (Â± 14 days) after the end of treatment. See Section 11.2. 
4Subjects taken off treatment without documented disease progression will be followed for disease progression every 3 months for 1 year .  
5See section 17.3 for Lugano staging system. 
6Vital signs to include blood pressure, heart rate, respi[INVESTIGATOR_697], weight, and height (screening only).  
7See section 17.4 for ECOG performance status scale.  
8CMP: sodium, potassium, chloride, creatinine, blood urea nitrogen; liver function tests (LFTs) : AST, ALT, total  bilirubin, alkaline phosphatase . 
9Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity of 25 IU/L or equivalent 
units of human chorionic gonadotropin) at screening and within [ADDRESS_1197544] will be required.   
10Tumor response assessment  by [CONTACT_10052]/CT will be performed within 30 days of C1D1; after cycles 4, 8, and 12; then every 8 cycles until 24 months 
after initiation of study treatment;  then every 6 months (every 12 cycles) until study discontinuation. If IR determined on response evaluation, 
repeat PET is required in 8 weeks to evaluate for response or progression.  Tumor response should also be evaluated at time of suspected clinical 
progression. If the patient achieves a CR, therapy will be continued for 6 months followed by [CONTACT_859366]/CT to confirm ongoing CR prior to 
therapy discontinuation (see section 5). PET/CT performed as SOC prior to signing consent may be used for study as long as it is  within the 30-
day screening window.  
11Bone marrow biopsy at screening  to include biopsy for immunohistochemistry and aspi[INVESTIGATOR_859331]. If bone marrow is pos itive and 
PET is negative for bone marrow uptake, then bone marrow biopsy will be repeated at the time a radiographic CR is observed to confirm a CR . If 
bone marrow is positive and PET is positive for bone marrow uptake, then a bone marrow biopsy is not ma ndatory for response assessment. For 
patients achieving a CR who have completed an additional 6 months of therapy, a bone marrow biopsy will be performed prior to treatment 
discontinuation to confirm ongoing CR.  If bone marrow and PET are negative, then a bone marrow biopsy will not be repeated unless deemed 
clinically necessary ( e.g. to evaluate cytopenias). Biopsies will be performed with in Â±7 days from the time that PET/CT confirms CR . 
12Fresh tumor biopsy is mandatory upon trial enrollm ent unless contraindicated .  FFPE and flash frozen cores for IHC testing for CSF -1R, PD-L1, 
lymphoma associated macrophage s (LAM), regulatory T cell s (Treg), and cytotoxic T lymphocyte s (CTL) must be available.  Biopsy samples will 
include FFPE for future analysis. See CLM for collection, processing, labeling and shippi[INVESTIGATOR_3931]. 
13Repeat tissue biopsy required  only at first imaging assessment (after cycle 4) if residual tumor exists on imaging  and disease i s amenable to 
biopsy. If CR achieved, then no biopsy required. If PR or better response achieved  during trial followed by [CONTACT_859367] e, then repeat biopsy requested  at 
the time of relapse. Window of Â±[ADDRESS_1197545] disease assessment (after 
C4) if a subject is not progressing and is tolerating the study drugs with minimal side effects.
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 36 of 84 7.1 Safety Follow- up Evaluations 
A safety follow-up visit should occur when subjects permanently stop study treatment for whatever 
reason (toxicity, progression, or at discretion of site investigator) and should be performed 30 days (Â±7 
days) after the last dose of treatment. Subjects who have an y ongoing â‰¥ grade 2 or serious AE (SAE) at 
this visit will continue to be follo wed until the AE resolves to â‰¤ Grade 1 or baseline, is deemed clinically 
insignificant, and/or until a new anti- cancer treatment starts, whichever is earlier.  AEs, both serious and 
non-serious, will be collected for 100 days after the end of treatment. See Section 11.2. 
7.2 Long Term Follow- up Evaluations 
All subjects will be followed until documented disease progression. Subjects who discontinue treatment 
for any reason without documented disease progression will be followed for disease progression every 3 
months (Â±1 4 days) for 1 year.  Follow up may be accomplished via clinic visit, phone call, or other 
avenues as appropriate. 
 
8. BIOSPECIMEN STUDIES AND PROCEDURES  
Biospecimens will be collected according to the schedule of events for correlative/exploratory endpoints 
as outlined below.   1) To examine lymphoma associated macrophage (LAM), regulatory T cell (Treg), and cytotoxic T lymphocyte (CTL) densities (before and during treatment) as pharmacodynamic and prognostic biomarkers.  
 Please see sections 1.2 and 1.3 for relevant background. Immunohistochemistry will be 
performed on pre- treatment biopsy material and serially compared with a paired â€œon treatmentâ€ 
biopsy performed after cycle 4 (in patients with disease that is amenable to  biopsy). We 
anticipate that therapy will be associated with significant macrophage depletion and increased CTL infiltration (and/or increase the ratio of CTL:Treg), and that these changes within the tumor 
microenvironment may  be predictive of response.  
 
2) To examine the role of PD-L1 and CSF-1R expression as pharmacodynamic and prognostic biomarkers. 
 Please see sections 1.2 and 1.3 for relevant background. Immunohistochemistry will be 
performed on pre- treatment biopsy material and serially compared with a paired â€œon treatmentâ€ 
biopsy performed after cycle 4 (in patients with disease that is amenable to  biopsy). We 
anticipate that pre-treatment PD -L1 and CSF-1R expression may be associated with a response 
to therapy. Treatment is anticipated to deplete CSF -1R expressing cells, including LAM.  
 
3) To examine the abundance of â€œexhaustedâ€ T cells in the peripheral blood as a pharmacodynamic and prognostic biomarker. 
 T cells that are chronically stimulated by [CONTACT_859368] â€œexhaustedâ€ [45]. T-cell exhaustion is characterized by [CONTACT_859369], loss of 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 37 of 84 effector functions, sustained upregulation of inhibitory receptors (e.g. PD- 1), and altered gene 
expression and metabolic reprogramming [ 45, 46].  
 
Immunophenotypi[INVESTIGATOR_859332] T cells will be performed by [CONTACT_4133]. The abundance of â€œexhaustedâ€ T cells will be determined by [CONTACT_137766][INVESTIGATOR_859333] (but are not limited to):  PD -1, LAG-3, CTLA-4, TIM-3, TIGIT, and 
2B4. We anticipate that therapy will decrease the frequency of exhausted T cells and that this may be associated with response.  
 
4) To evaluate the feasibility and utility of minimal residual disease (MRD) monitoring as a pharmacodynamic and prognostic biomarker. 
 Despi[INVESTIGATOR_859334] T-cell antigens, expression of the T- cell receptor (TCR) is  retained in 
>90% of PTCL, NOS (reviewed in [ 47]). This observation suggests that the TCR may play a 
pathogenic role in PTCL. In fact, we have found that TCR engagement in primary malignant T cells leads to widespread changes in gene expression and the activation of important transcription factors, including NF-ÎºB and GATA-3 (data not shown). Furthermore, TCR  
engagement promotes growth, survival, and resistance to chemotherapy (data not shown). These selective pressures apparently favor maintenance of TCR expression in PTCL and suggest that the TCR is an attractive candidate for MRD monitoring by [CONTACT_5019]-throughput sequencing (HTS). HTS of the third complementarity determining region (CDR3) of the TCRÎ² or TCRÎ³ genes is able to identify and quantify the relative frequency of clonal T cells in T-cell lymphomas[ 48-52].  
 High throughput screening of CDR3 of the T cell receptor Î² or Î³ genes will be used to identify  
and quantify the relative frequency of clonal T cells in patients who achieve a CR. We will also use stored samples from these patients collected at time points prior to frank relapse to determine whether MRD monitoring can be used as a predictor of relapse. We anticipate that detection of MRD in patients with CR will b e predictive of future relapse.  
 
5) To evaluate the role of myeloid derived suppressor cells (MDSC) as a pharmacodynamic and prognostic biomarker. 
 MDSC are not a discrete subset of myeloid-derived cells, but are a heterogenous population of 
immature myeloid cells functionally defined by [CONTACT_859370]. In humans, 
MDSC express the common myeloid marker CD33, are CD11b+HLA- DR-/low and generally 
lineage negative (Lin -) (37-39). They  may also variously express the granulocytic marker 
CD15[53] or the monocytic marker CD14 [ 54, 55], suggesting the presence of both granuloc ytic 
and monocytic MDSC [ 22, 56]. MDSC (or at least cells with an identical immunophenotype) 
comprise only a s mall percentage of (~0.5%) of peripheral blood mononuclear cells in normal 
humans [22, 57]. During a systemic inflammatory state, as may be observed in malignancy , 
MDSC greatly expand in response to both tumor- and stromal- derived factors and accumulate 
within the bone marrow, peripheral blood, spleen, lymph nodes, liver and tumors [ 22, 54, 58-67].  
 The mechanism of MDSC immunosuppression is mediated by a number of factors including expression of arginase (ARG1), inducible nitric oxide synthase (iN OS) [68-70], transforming 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 38 of 84 growth factor beta (TGF-Î² ) [71, 72], IL-10[73], cyclooxygenase -2 (COX2) [74], sequestration of 
cysteine [75], and induction of Treg [ 76].  
 
Recently, MDSCs were shown to correlate with clinical outcome of patients treated with ipi[INVESTIGATOR_125] [77, 78] or other immunomodulatory therapi[INVESTIGATOR_859335] -2 [79] or antitumor vaccines 
[80]. These studies highlight the potential role of MDSCs as a valuable biomarker for response to 
immunotherapi[INVESTIGATOR_859336], as is possible with CSF1-R blockade, can lead to improved responses to such therapi[INVESTIGATOR_014] [ 81].  
 To evaluate the role of MDSC in PTCL patients treated with immunotherapi[INVESTIGATOR_014], we will quantify the proportion of circulating MDSC and  myeloid dendritic cells in patients pre and post 
treatment by [CONTACT_4133]. We anticipate that treatment will result in depletion of circulating 
MDSCs and will be predictive of response.   
6) To biobank diagnostic biopsy specimens and other biologic specimens or blood for future correlative studies which may include somatic mutation testing and/or immune cell and cytokine analyses. 
8.1 Source and Timing of Biospecimen Collections 
Tissue collection : 
Fresh tumor biopsy is mandatory pri or to treatment unless contraindicated .  Biopsy samples will include 
FFPE and flash frozen tissue for future analysis. Repeat biopsy (if tissue available) is also required after 
cycle 4 of treatment.  Repeat biopsy is requested at the time of relapse if PR or greater achieved while on 
trial. See CLM for collection, processing, labeling and shippi[INVESTIGATOR_3931]. 
 
Blood Collections: 
Whole blood will be collected and processed for PBMCs, serum, and plasma at C1D1, C3D1, C5D1, 
every timepoint for response assessment  thereafter , and at 30 day safety follow up. 
 Whole blood for future somatic baseline will be collected at pre- treatment C1D1.  
8.2 Storage of Biospecimens  
Patient samples (tissue, blood, serum, plasma) collected for this study will be retain ed at the Hoosier 
Cancer Research Network, as Administrative Headquarters for the B ig Ten CRC. Coded specimens will 
be stored indefinitely or until they are used up. If consent for future use of specimens is withdrawn by [CONTACT_423], best efforts will be made to stop any additional studies and to destroy the specimens. 
8.[ADDRESS_1197546] consent will be obtained to bank any leftover samples that were collected for study- specific 
correlative research. Hoosier Cancer Research Network  (HCRN), as Administrative Headquarters for 
the Big Ten CRC, will manage the banked samples. Samples will be banked indefinitely in the Hoosier 
Cancer Research Network Biorepository  and used for future unspecified cancer -related research.  
8.[ADDRESS_1197547]  additional samples collected for future unspecified Big Ten 
Cancer Research Consortium studies. HCRN will manage the banked samples. Samples will be banked 
indefinitely in the HCRN Biorepository.  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 39 of 84  
This includes: 
â€¢ Whole blood: Whole blood will be collected prior to treatment on C1D1, C3D1, C5D1, every 
timepoint for response assessment thereafter, and at 30 day safety follow up. 
â€¢ Pre- and Post-treatment serum: Whole blood for serum will be collected prior to treatment on C1D1, 
C3D1, C5D1, every timepoint for response assessment thereafter, and at 30 day safety follow up. 
â€¢ Unstained slides: Unstained slides will be obtained from the subjectâ€™s formalin fixed paraffin embedded tumor sample.  
 Please refer to the Correlative Laboratory M anual (CLM)  for all sample collection, processing, labeling, 
and shippi[INVESTIGATOR_3931]. 
8.[ADDRESS_1197548]â€™s study number assigned at the time of registration to the trial. 
Any material issued to collaborating researchers will be anonymized and only identified by [CONTACT_423]â€™s study number. 
9. CRITERIA FOR DISEASE EVALUATION  
Response evaluations will be performed  in accordance with the provisional Lugano lymphoma response 
to immunomodulatory therapy criteria (LYRIC) which incorporates a new response category, 
indeterminate response (IR) [82]. See Section 17.5. 
 
Immune checkpoint inhibitors, have demonstrated impressive activity in a broad range of lymphoma histologies. However, these agents may be associated with clinical and imaging findings during treatment suggestive of progressive disease (PD) despi[INVESTIGATOR_859337] (eg, tumor flare or pseudoprogression). Considering this finding as PD could lead to patients being prematurely removed from a treatment from which they actually stand  to benefit. This phenomenon has been well described 
with checkpoint blockade therapy in solid tumors and anecdotally seen in lymphoma as well. To address this issue in the context of lymphoma immunomodulatory therapy, a workshop was convened to provide provisional recommendations to modify current Lugano response criteria in patients receiving these and future agents in clinical trials. The criteria are largely in keepi[INVESTIGATOR_859338][83]  but the term â€œindeterminate responseâ€ (IR) was introduced within the LYRIC criteria  to 
identify such lesions until confirmed as flare/pseudo-progression or true PD by [CONTACT_128931].   The term IR does not make direct reference to the underlying mechanism, recognizing that a delayed response and an immune mediated flare can both occur in the early treatment period and may be difficult to distinguish from progression by [CONTACT_859371]. Moreover, the term provides the flexibility to allow patients  to continue treatment past IR in some circumstances with a mandatory 
subsequent response evaluation to confirm or refute true PD.   IR categories are defined as:  
â€¢ IR1: Increase in overall tumor burden (as assessed by [CONTACT_859372] [SP D]) 
of â‰¥ 50% of up to [ADDRESS_1197549] 12 weeks of therapy, without clinical deterioration. 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 40 of 84 â€¢ IR2: Appearance of new lesions or growth of one or more existing lesion(s) â‰¥50% at any time 
during treatment; occurring in the context of lack of overall progression (<50% increase) of overall tumor burden, as measured by [CONTACT_61904] 6 lesions at any time during the treatment.  
â€¢ IR3: Increase in FDG uptake of 1 or more lesion(s) without a concomitant increase in lesion size or number. 
 It is possible that, at a single time point, a patient could fulfill criteria for both IR1 or IR2 and IR3. F or 
example, there could be a new  FDG avid lesion in the absence of overall progression (IR2),  and, at the 
same time, increase in FDG  uptake of a separate lesion (IR3). In such cases, the designation IR1 or IR2  
should take priority (i.e.  IR2 in the above example).  
 As a secondary endpoint, patients will also be evaluated for response by [CONTACT_415580] 2014 criteria (Section 17.6).  
9.[ADDRESS_1197550] target nodes, nodal masses, or extranodal  lesions that are measurable in two 
diameters (longest diameter [LDi] and shortest diameter [SDi]) should be identified from different body 
regions representative of the patient's overall disease burden and include mediastinal and retroperitoneal 
disease, if involved. Measurable extranodal disease (eg, hepatic, splenic, renal, or pulmonary nodules) 
may be included in the six representative, measured lesions.  A measurable node must have an LDi greater than 1.[ADDRESS_1197551] an LDi greater than 1.0 cm. All other lesions (including nodal, extranodal, and assessable disease) should be followed as nonmeasured disease (eg, cutaneous, GI, bone, spleen, liver, kidneys, pleural or pericardial effusions, ascites).  
9.[ADDRESS_1197552] Overall Response 
Based on definitions provided in section 17.5  9.3 Definitions for Response Evaluation â€“ LYRIC criteria  
See section 17.5 for table outlining response criteria including indeterminate response (IR) criteria.  
 In patients categorized as having IR (described in section 9), it is  mandatory to obtain a repeat imaging 
after an additional 8 weeks (or earlier if clinically indicated). At that time, response should be re -
evaluated, and the patient should be considered to have true PD if the SPD of target lesion has increased further, with the considerations below:  
â€¢ In the case of  IR1, the comparison should be between the first IR1 and the current SPD, with an 
increase of â‰¥10% constituting PD. In addition, there should be an increase of â‰¥5 mm (in either dimension) of â‰¥1 lesion for lesions â‰¤2 cm and 10 mm for lesions >2 cm, to be consistent with the Lugano classification. The 10% threshold is empi[INVESTIGATOR_859339] f or variability in 
measurement,  especially wh en taken along with the minimum increase. If the target SPD 
increase is <10%, the respons e would still be categorized as IR1 , and the patient could continue 
treatment until a subseq uent scan shows either true PD ( â‰¥10% increase from first  IR1 time point 
and an increase of >5 mm in either dimension of â‰¥1 lesion) or response (â‰¥50% decrease from 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 41 of 84 baseline). In this situation, repeat imaging in 8 weeks of the original IR1 time point to ensure 
absence of significant further increase.  
â€¢ In the case of IR2 , the new or growing lesion(s) (unless biopsy proven to be benign) should be 
added to the target lesion(s), up to a total of no more than 6 total lesions. If the SPD of the newly 
defined set of target lesions has increased â‰¥50% from their nadir value (which may precede the IR time point), the patient should be considered to have PD. 
â€¢ In the case of IR3 , because inflammatory responses may result in an increase in the standardized 
uptake value of a lesion, the patient will not be considered to have PD unless there is evidence of PD by [CONTACT_859373], as noted above. 
 If a patient is assessed as having IR and then â€œtrueâ€ PD at a subsequent time point (without an intervening objective response between IR and PD), the IR assessment should subsequently be corrected to PD for reporting purposes to the date of the prior designation of IR. 
9.3.[ADDRESS_1197553] documentation of PR or CR. 9.3.2 Objective Response Rate  
The objective response rate is the proportion of all subjects with confirmed PR or CR . 
9.3.3 Complete Response Rate 
The complete response rate is the proportion of all subjects with confirmed CR . 
9.3.4 Progression Free Survival  
A measurement from the date of enrollment until the criteria for disease progression  (PD) is met or 
death occurs. Subjects who have not progressed will be right- censored at the date of the last disease 
evaluation. 9.3.5 Disease Control Rate 
The disease control rate (DCR) is the proportion of all subjects with stable disease (SD) for 8 weeks , 
PR, or CR. 
9.3.6 Duration of Response 
Duration of response is the period measured from the time that measurement criteria are met for CR or 
PR (whichever status is recorded first) until the date that recurrent or progressive disease is objectively 
documented (taking as reference for progressive disease the smallest measurements recorded since 
treatment starte d). 
9.3.7 Time to Next Treatment  
The time to next treatment (TNT) is defined as the time from the date of enrollment to  the institution of 
next treatment.   
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197554] version of the prescribing information that can be found at 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ , and/or on the manufacturerâ€™s website. 
 For cabiralizumab, please refer to the current version of the Investigatorâ€™s Brochure (IB) f or additional  
information regarding this drug. 
10.1 Cabiralizumab 
Cabiralizumab (BMS-986227, FPA008) is a recombinant, humanized Immunoglobulin G4 (IgG4) 
monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c- fms). It is 
currently undergoing investigation in clinical trials, but has not yet been approved for commercial use. 
10.1.1 Supplier/How Supplied  
Bristol-Myers Squibb will supply cabiralizumab at no charge to subjects participating in this clinical 
trial. At the end of the study period, Bristol-Myers Squibb Company will not continue to supply study 
drug to subjects/investigators unless the Sponsor-Investigator chooses to extend their study. The investigator is responsible to ensure that the subject receives appropriate standard of care or other appropriate treatment in the independent medical judgement of the Investigator to treat the condition under study.   The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution, and usage of investigational product in 
accordance with the protocol and any applicable laws and regulations. 
10.1.[ADDRESS_1197555] in 0.9% sodium 
chloride or 5% dextrose injection. Since cabiralizumab solution contains no preservatives, diluted solutions for infusion should be administered or discarded within four hours after preparation. The IV administration set for cabiralizumab infusion must contain a 0.[ADDRESS_1197556] is shipped refrigerated at 2â€“8Â°C and stored refrigerated at 2â€“8Â°C until time 
of use. The contents of the vials supplied are sterile, pyrogen-free, and contain no preservatives. Vials are for single -use only. Drug product should be protected from light. 
10.1.[ADDRESS_1197557] common adverse events reported with cabiralizumab monotherapy include periorbital, facial, local and peripheral edema, pruritus, rash, and elevated lab values (CK, LDH, AST, ALT).   Hypersensitivity and/or infusion reaction is the most common toxicity with the use of monoclonal antibodies. There have been no infusion reactions or hypersensitivity reactions reported from any patients treated with cabiralizumab monotherapy to date while one patient in FPA008-[ADDRESS_1197558] been noted, macrophages play a role in innate immunity, and treatment with cabiralizumab may be associated with increased susceptibility to infections. Patients should be routinely monitored for signs and symptoms of infections during cabiralizumab treatment according to the clinical protocol.  
 In combination with nivolumab, the adverse event profile (other than infusion reactions as noted above) is similar to each agent individually.  
10.2 Nivolumab 
Nivolumab (also referred to as BMS -936558, MDX1106, or ONO-4538) is a human monoclonal 
antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD -1) 
cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by [CONTACT_93247] T and B lymphocytes.1 Binding of PD- 1 to its lig ands, programmed 
deathâ€“ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. 
Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T -cell responses to both foreign anti gens as well as  self-antigens. 
 Nivolumab is approved in the [LOCATION_002] for use in melanoma, non- small cell lung cancer, renal cell 
carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, and urothelial carcinoma.  
10.2.1 Supplier/How Supplied  
Bristol-Myers Squibb will supply nivolumab at no charge to subjects participating in this clinical trial.  
At the end of the study period, Bristol-Myers Squibb Company will not continue to supply study drug to subjects/investigators unless the Sponsor-Investigator chooses to extend their study. The investigator is responsible to ensure that the subject receives appropriate standard of care or other appropriate treatment in the independent medical judgement of the Investigator to treat the condition under study.   
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197559] in accordance with the protocol and any applicable laws and regulations. 
10.2.2 Preparation  
Nivolumab injection is to be administered as an IV infusion through a 0.2-micron to 1.2-micron pore 
size, low-protein binding (polyethersulfone membrane) in- line filter at the protocol-specified doses and 
infusion times. It is not to be administered as an IV push or bolus injection. Nivolumab injection can be infused undiluted (10 mg/mL) or diluted with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to protein concentrations as low as 0.35 mg/mL.   During drug product preparation and handling, vigorous mixing or shaking is to be avoided. Care must be taken to assure sterility of the prepared solution as the product does not contain any antimicrobial preservative or bacteriostatic agent. Nivolumab infusions are compatible with polyvinyl chl oride (PVC) 
or polyolefin containers and infusion sets, and glass bottles. 
10.2.[ADDRESS_1197560] be stored at 2ÂºC to 8ÂºC (36 ÂºF to 46ÂºF) and protected from light and 
freezing. 
 
The administration of nivolumab infusion must be completed within 24 hours of preparation. If not used immediately, the infusion solution may be stored under refrigeration conditions (2Â°C to 8Â°C, 36Â°F to 46Â°F) for up to 24 hours, and a maximum of 8 hours of the total 24 hours can be at room temperatur e 
(20Â°C to 25Â°C, 68Â°F to 77Â°F) and room light. The maximum of [ADDRESS_1197561] common adverse events include pneumonitis, colitis, diverticular perforation, hepatitis, endocrinopathies (hypophysitis, thyroiditis, adrenal insufficiency), pancreatitis, asymptomatic amylase/lipase elevations, 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 45 of 84 rash, pruritus, nephritis, encephalopathy, aseptic meningitis, peripheral sensory/motor neuropathies 
(Guillain-Barre, myasthenia gravis), infusion reactions (rare), uveitis, and myopathy including 
myocarditis.  
 In combination with cabiralizumab, the adverse event profile appears similar to each agent individually . 
11. ADVERSE EVENTS  
11.1 Definitions  
11.1.1 Adverse Event  (AE) 
An AE is any untoward medical occurrence whether or not considered related to the study drug that 
appears to change in intensity during the course of the study. The following are examples of AEs:  
â€¢ Unintended or unfavorable sign or symptom 
â€¢ A disease temporal ly associated with participation in the protocol 
â€¢ An intercurrent illness or injury that impairs the well-being of the subject 
 Abnormal laboratory values or diagnostic test results constitute AEs only if they induce clinical signs or symptoms or require treatment or further diagnostic tests    Hospi[INVESTIGATOR_129297] (e.g., surgical insertion of central line) should not be recorded as an AE.  
11.1.2 Serious Adverse Event  (SAE) 
An SAE is an adverse event that : 
â€¢ Results in d eath. NOTE: Death due to disease progression should not be reported as a S AE, 
unless it is attributable by [CONTACT_3987](s) 
â€¢ Is life-threatening (defined as an event in which the subject was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it were more 
severe) 
â€¢ Requires inpatient hospi[INVESTIGATOR_272] >24 hours or prolongation of existing hospi[INVESTIGATOR_059]. 
NOTE: Hospi[INVESTIGATOR_693937], central line insertion, metastasis interventional therapy, resection of primary tumor, or elective surgery, will not be considered serious adverse events. 
â€¢ Results in persistent or significant disability/in capacity 
â€¢ Is a congenital anomaly or birth defect 
â€¢ Is an important medical event (defined as a medical event(s) that may not be immediately life -
threatening or result in death or hospi[INVESTIGATOR_313], based upon appropriate medical and scientific judgment, ma y jeopardize the subject or may require intervention (e.g., medical, 
surgical) to prevent one of the other serious outcomes listed in the definition above). Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions not resulting in hospi[INVESTIGATOR_059]; or the development of drug dependency or drug abuse. 
â€¢ Is an overdose (defined as the accidental or intentional administration of any dose of a product that is considered by [CONTACT_859374].) All occurrences of overdose must be reported as an SAE. 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 46 of 84 â€¢ Although pregnancy, overdose, potential drug-induced liver injury (DILI), and cancer are not 
always ser ious by [CONTACT_8661], these events must be handled as SAEs. 
11.1.3 Unexpected Adverse Event  
For this study, an AE is considered unexpected when it varies in nature, intensity or frequency from information provided in the current IB, package insert, or wh en it is not included in the informed 
consent document as a potential risk. Unexpected also refers to AEs that are mentioned in the IB as occurring with a class of drugs or are anticipated from the pharmacological properties of the drug, but 
are not specif ically mentioned as occurring with the particular drug under investigation.   
 
11.1.4 Relatedness  
AEs will be catego rized accordi ng to the likelihood that they are related to the study drug(s). 
Specifical ly, they will be categorized using the following terms: Relatedness  
 
Unrelated  The Adverse Event is not related  to the drug(s)  
Unlikely The Adverse Event is doubtfully related  to the drug(s)  
Possible The Adverse Event may be related  to the drug(s)  
Probable The Adverse Event is  likely related  to the drug(s)  
Definite The Adverse Event is clearly related  to the drug(s)  
11.1.[ADDRESS_1197562] 5 half -lives after study 
drug administration, the study drug will be permanently discontinued in an appropriate manner (e.g., dose tapering if necessary for subject safety).   The site investigator must immediately notify B ig Ten CRC AHQ of this event via the SAE Submission 
Form in accordance with SAE reporting procedures. Big T en CRC AHQ will then notify Worldwide 
Safety at BMS.  
 Protocol-required procedures for study discontinuation and follow-up must be performed.  Follow-up information regarding the course of the pregnancy, including perinatal and neonatal outcome and, where applicable, offspring information must be reported on the SAE Submission Form.  
 Any pregnancy that occurs in a female partner of a male study participant should be reported to Big T en 
CRC AHQ via the SAE Submission Form in accordance with SAE reporting procedures. Big T en CRC 
AHQ will then notify Worldwide Safety at BMS.  
11.1.6 Drug Induced Liver Injury (DILI)  
All occurrences of potential DILIs, meeting the defined criteria, must be reported as SAEs. Potential drug induced liver injury is defined as: 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197563] or ALT lab value that is greater than 3  Ã— the upper limit of normal, and   
2. an elevated total bilirubin lab value that is greater than 2 Ã— the upper limit of normal  without 
initial findings of cholestasis (elevated serum alkaline phosphatase),  and ,  
3. No other immediately apparent possible causes of aminotransferase (ALT or AST)  elevation and 
hyperbilirubinemia, including, but not limited to, viral hepatitis, pre-existing chronic or acute 
liver disease, or the administration of other drug(s) known to be hepatotoxic. 
 DILIs that occur in any subject from the date of first dose through [ADDRESS_1197564] be reported to Big Ten CRC AHQ within 24 hours/ 1 business day using the SAE Submission Form (see Documents/Info tab of the EDC ). The form 
may be sent electronically to [EMAIL_038]
. Big Ten CRC AHQ will notify Worldwide 
Safety at BMS  within 24 hours/ 1 business day. 
11.2 Reporting  
11.2.1 Adverse Events  
â€¢ AEs will be recorded from time of signed informed consent until 100 days after  discontinuation 
of study drug(s ). 
â€¢ AEs will be recorded  regardless of whether or not they are considered related to the study 
drug(s).   
â€¢ All AEs will be recorded in the subjectâ€™s medical record and on the appropriate study specific 
eCRF form within the EDC system. 
â€¢ All AEs considered related to study drug(s) will be followed until resolution to â‰¤ Grade 1 or 
baseline, deemed clinically insignific ant, and/or until a new anti -cancer treatment starts , 
whichever occurs first . 
â€¢ Asymptomatic laboratory abnormalities that do not require treatment will not be collected as 
adverse events.  
[IP_ADDRESS] Big Ten CRC AHQ Requirements for Reporting AEs to Bristol -Myers Squibb 
Adverse Events that are routinely collected according to G ood Clinical Practice wi ll be submitted to BMS 
every three (3) months by [CONTACT_631259].  The Adverse Event information required to be sent to BMS as noted in the â€˜Bristol-Myers Squibb Early 
Asset Investigator Sponsored Research (ISR) Import Plan.â€™ This document describes the method of 
collection and submission to BMS via the mailbox: 
[EMAIL_14389]
 
When the file is submitted to BMS, it will be noted that the file contains  non-serious AEs not previously 
submitted to BMS within the previous 3 months. 
 11.2.2 Serious Adverse Events (SAEs)  
[IP_ADDRESS] Site Requirements  for Reporting SAEs  to Big Ten CRC Administrative Headquarters  
â€¢ SAEs will be reported from time of signed informed consent until 100 days after  discontinuation 
of study drug(s).  
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 48 of 84 â€¢ SAEs will be reported on the SAE Submission Form and entered in the SAE tab in the EDC  
system within 1 business day  of discovery of the event.   
â€¢ SAEs include events related and unrelated  to the study drug(s).  
â€¢ All SAEs will be recorded in the subjectâ€™s medical record and on the appropriate study specific 
eCRF form within the EDC system.   
â€¢ All SAEs regardless of relation to study drug will be followed until resolution to â‰¤ Grade 1 or 
baseline and/or deemed clinically insignificant and/or until a new anti- cancer treatment starts,  
whichever occurs first.  
 
The site will submit the completed SAE Submission Form (see Documents/Info tab of the EDC ) to Big 
Ten CRC AHQ  within 1 business day  of discovery of the event. The form may be sent electronically to 
[EMAIL_038] . If only limited information is initially available, follow -up reports are 
required.  
 The site investigator is responsible for informing the IRB and/or other local regulatory bodies of the 
SAE as per local requirements.  
 The original copy of the SAE Submission Form and the email correspondence must be kept within the study file at the study site.  
 If an ongoing SAE changes in its intensity, relationship to study drug, or if new information becomes 
available, sites must submit a follow up SAE Submission Form within 1 business day to Big T en CRC 
AHQ electronically  at [EMAIL_038]
. (Note: Follow -up SAE reports should include the 
same investigator term(s) initially reported.)  
[IP_ADDRESS] Big Ten CRC AHQ  Requirements for Reporting SAEs to Bristol -Myers Squibb   
Big Ten CRC AHQ  will report all SAEs, regardless of relationship to study drug, to Bristol- Myers 
Squibb within 24 hours/1 business day of receipt of the SAE Reporting Form.  Follow-up information 
will be provided to Bristol-Myers Squibb as reasonably requested.   
SAE Email Address:  [EMAIL_176]  
SAE Facsimile Number:  +[PHONE_1161] 
Follow-up SAE reports will be sent by [CONTACT_859375] 24 hours/1 business day to BMS (or 
designee) using the same procedure used for transmitting the initial SAE report.  
 SAE Reconcil iation: 
On behalf of the Sponsor Investigator, Big T en CRC AHQ will ensure that all SAEs in the clinical 
database are reported to BMS and any applicable health authority during the conduct of the study. This reconciliation will occur at least quarterly and  be initiated by [CONTACT_859376] T en CRC AHQ. Big T en CRC AHQ 
will request a reconciliation report from: [EMAIL_177]
. During reconciliation, any 
events found to not be reported previously to BMS must be sent to [EMAIL_176] . 
 All SAEs should be faxed or emailed to BMS at: 
Global Pharmacovigilance & Epi[INVESTIGATOR_34237]-Myers Squibb Company  
Fax Number: [PHONE_188] 
Email: [EMAIL_178]
 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 49 of 84 [IP_ADDRESS] Sponsor-Investigator Responsibilities 
Big Ten CRC AHQ  will send a SAE summary to the sponsor-investigator and the Michigan Institute for 
Clinical and Health Research (MICHR) IND/IDE Investigator Assistance Program (MIAP)  within 1 
business day  of receipt of SAE Submission Form from a site.  The sponsor- investigator will promptly 
review the SAE summary and assess for expectedness and relatedness.  
[IP_ADDRESS] Michigan Institute for Clinical and Health Research (MICHR) IND/IDE Investigator 
Assistance Program (MIAP)  Responsibilities for Reporting SAEs to FDA 
MICHR-MIAP is responsible for manag ing the Investigational New Drug Application (IND) associated 
with this protocol on behalf of the sponsor- investigator .  Big Ten CRC AHQ  will obtain a copy of the 
cross-reference letter(s) from  Bristol-Myers Squibb and provide to MICHR- MIAP for the IND 
application ( [EMAIL_16274] ). MICHR-MIAP will cross -reference this submission to 
Bristol-Myers Squibbâ€™s parent IND at the time of submission. MICHR -MIAP will provide Big T en CRC 
AHQ with a copy of the application and Big T en CRC AHQ will p rovide a copy of these documents to 
Bristol-Myers Squibb. 
 MICHR-MIAP will be responsible for all communication with the FDA in accordance with 21CFR312 
which includes but is not limited to  the [ADDRESS_1197565] . 
[IP_ADDRESS] IND Safety Reports Unrelated to this Trial  
Bristol-Myers Squibb will provide Big T en CRC AHQ with IND safety reports from external studies 
that involve the study drug(s) per their guidelines. Big T en CRC AHQ  will forward the safety reports to 
the sponsor-investigator who will review these reports and determine  if revisions are needed to the 
protocol or consent.  Big T en CRC AHQ  will forward these reports to participating sites within 1 
business day  of receiving the sponsor-investigatorâ€™s review. Based on the sponsor-investigatorâ€™s 
review, applicable changes will be made to the protocol and informed consent document (if required). Any changes made to the protocol and/or informed consent document will be submitted to the FDA by [CONTACT_501317]-MIAP. All IND s afety reports will also be made available to sites via the EDC system. 
 Upon receipt from Big T en CRC AHQ , site investigators (or designees) are responsible for submitting 
these safety reports to their respective IRBs, as per their IRB policies.  
12. STATISTICAL METHODS  
12.1 Study Design  
This is a phase II single arm, non-randomized, open label trial with an interim futility /safety analysis.  
12.2 Endpoints  
12.2.1 Definition of Primary Endpoint s 
See Section 9.3. 
12.2.2 Definition of Secondary Endpoints  
See Section 9.3 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 50 of 84 12.3 Sample Size, Accrual , and Interim Futility Anal ysis 
We propose a two -stage design with co -primary endpoints of complete response (CR) and overall 
response (OR), testing a â€œboth-andâ€ null hypothesis against an â€œeither-orâ€ alternative hypothesis. 
Specifically, we posit that a CRR of 30% or ORR of 60% is achievable (note that CRR refers to the marginal CRR, that is, the complete response rate without respect to overall response status, and not the 
conditional  CRR, which would be the complete response rate among any responders). Initially, 17 
eligible patie nts will be followed for response. At this point, if fewer than 3 patients demonstrate CR 
(<18%) and fewer than 7 patients demonstrate OR (<41%), the trial will be stopped for futility.   Otherwise, we will enroll an additional [ADDRESS_1197566] 7 patients (out of 33 total) demonstrate CR (21%) or at least 17 patients demonstrate OR (52%).   We will also formally incorporate three Grade 4+ adverse event (AE) threshold s that will activate at 
the interim analysis. First, if the number of patients with any Grade 4 AE is greater than or equal to 7 
(7/17=41%) by [CONTACT_145864], enrollment will stop. Second, if the number of patients with 
Grade 4 AEs that require discontinuation of study treatment, as specified in section 6.3, is greater 
than or equal to 3 (3/17=12%) by [CONTACT_145864] , enrollment will stop. Third, enrollment will 
stop at the interim analysis for any Grade 5 AE attributable to drug.  To demonstrate the operating characteristics of this design, we simulated repeated trials under a grid of 
different true values of CRR , ORR, and Grade 4+ AE rate. When the true CRR and ORR are 
simultaneously no greater than 10% and 30%, respectively, and the true Grade 4+ AE rate is 32%, this 
design will successfully conclude with probability less than 0.05 (one-sided type I error) and stop ( for 
futility or safety collectively) at the interim analysis with probability about 0.75.  When the true CRR is 
at least 30% or the true ORR is at least 60%, this design will successfully conclude with probability at 
least 0.62 (power) and stop at the interim analysis with probability at most 0.34. The schematic in Figure 
1, immediately below, gives the full operating characteristics over all considered combinations of CRR 
and ORR when the true Grade 4+ AE rate is 32%. The blue-purple region denotes the true generating 
scenarios satisifying the â€˜either -orâ€™ hypothesis, wherein at least one of the efficacy thresholds is met or 
exceeded. The green region denotes satisifying neither the null nor the alternative hypothesis, wherein both efficacy rates exceed their null values but neither meets the alternative. The red region denotes the â€˜both-andâ€™ null hypothesis.   
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 51 of 84  
Figure 1: Probability of declaring success and, in parentheses, probability of stoppi[INVESTIGATOR_859340], when the true Grade 4+ AE rate is 32%. 
To demonstrate the effect of our toxicity stoppi[INVESTIGATOR_1877], Figure 2 below gives the operating 
characteristics of our design when the true Grade 4+ AE rate is 50%. The entire region is shaded red, 
because the treatment regimen is unacceptably toxic. The probability of declaring success, even wh en 
one of the efficacy thresholds is satisfied in truth , is always less than 0.16, and the trial stops at the 
interim analysis with probability at least 0. 83.  
 
Figure 2: Probability of declaring success and, in parentheses, probability of stoppi[INVESTIGATOR_859341] y, when 
the true Grade 4+ AE rate is 50%. 
 Peripheral T -cell lymphoma response and progression will be assessed using the LYRIC cri teria as 
outlined in section 9.   Safety assessments will consist of the surveillance and recording of AEs and documentation of physical examination findings and laboratory data. Type, incidence, severity, seriousness, and relatedness of adverse events will be recorded. Additional secondary analyses include PFS, DCR, DOR, and TNT. 

Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197567] their disease re -evaluated will be evaluable for assessment of objective response. 
12.6 Data Analysis Plans 
The primary analysis will compare the observed OR and CR rates to posited null values of 30% and 
10%, respectively. We will calculate score-based confidence intervals for binomial proportions. At the critical values of 17/33 and 7/33, the confidence intervals for the ORR and CRR would be (35.2%, 67.5%) and (10.7%, 37.8%), respectively.The analyses of secondary safety objectives will be conducted using tabulations of adverse events, stratified by [CONTACT_859377].   The analyses corresponding to secondary efficacy endpoints ( PFS, DCR, DOR, TNT ) will be 
summarized with typi[INVESTIGATOR_2855] â€˜time -to-eventâ€™ analyses.  
 With regard to the exploratory objectives, we will evaluate pre-post changes in LAM, Treg,CTL, â€œexhaustedâ€ T cell, and MDSC  densities, as well as lymphoma cell and tumor microenvironment 
expression of PD-L1 and CSF-1R. We posit that changes in some or all of these biomarkers will correlate with response, thus demonstrating potential as prognostic biomarkers. We will als o evaluate 
MRD status in patients achieving CR and hypothesize that patients with CR but detectable MRD will predict relaps.  We will quantify these associations using visual and statistical summarization.   
12.6.1 Analysis Plans for Primary Objective 
See section 12.3. 
12.6.2 Analysis Plans for Secondary Objectives 
See section 12.3. 
12.6.3 Subgroup Analyses  
There are no subgroup analyses planned 
12.6.4 Other Planned Analyses  
There are no other planned analyses. 
13. TRIAL MANAGEMENT  
 
13.1 Data and Safety Monitoring Plan (DSMP)  
The Data and Saf ety Monitoring Committee (DSMC) of The University of Michigan Rogel Cancer 
Center is responsible for monitoring the safety and data integrity of the trial. 
 Big Ten CRC AHQ  oversight activities include : 
â€¢ Review and process all adverse events requiring expedited reporting as defined in the protocol 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 53 of 84 â€¢ Provide timely reports to MICHR- MIAP ([EMAIL_16274] ) that require 
expedited reporting 
â€¢ Notify participating sites of adverse events requiring expedited reporting 
â€¢ Provide trial accrual progress , safety information , and data summary reports to the sponsor-
investigator and MICHR- MIAP 
â€¢ Coordinate quarterly  meetings  for this phase II study. These meetings will include each accruing 
siteâ€™s principal in vestigator, clinical research specialist and/or research nurse (other members per 
principal investigatorâ€™s discretion).  
â€¢ The quarterly study team meetings will discuss matter s related to:  
o Enrollment rate relative to expectations, characteristics of partici pants 
o Safety of study participants (Serious Adverse Event reporting) 
o Adherence to protocol (protocol deviations) 
o Completeness, validity and integrity of study data 
o Retention of study participants 
â€¢ These meetings are to be documented by [CONTACT_16540] (DSMR), signed by [CONTACT_88333] [INVESTIGATOR_17780]-investigator . Big Ten CRC AHQ will assist in this process. The DSMR 
can be found in the Documents/ Info tab of the EDC.  Each  site is required to submit the completed 
DSMR to B ig Ten CRC AHQ on a quarterly basis together with other pertinent documents for 
submission to the DSMC. 
13.[ADDRESS_1197568] has completed the study drug interventions. Documentation of DSMC reviews will be provided to sponsor-investigator and Big T en CRC AHQ.  Issues of immediate con cern by [CONTACT_859378]- investigator and other regulatory bodies as appropriate. 
The sponsor- investigator will work with B ig Ten CRC AHQ and MICHR- MIAP to address the DSMCâ€™s 
concerns.  
 The DSMC will provide the sponsor-investigator and Big T en CRC AHQ evidence of its review. B ig 
Ten CRC AHQ will distribute this information to the participating sites for submission to their 
respective IRB per the local IRBâ€™s policies and procedures.  
 13.3 Data Quality Oversight Activit ies 
Remote v alidation of the EDC  system data will be completed on a continual basis throughout the life 
cycle of the study.  A summary report (QC Report) of these checks together with any queries resulting from manual review of the eCRFs will be generated for each site and transmitted to the site and the site 
monitor. Corrections will be made by [CONTACT_3991].  Monitoring visits to the trial sites will be made periodically during the trial to ensure key aspects of the 
protocol are followed. Additional for cause visit s may occur as necessary . Source documents will be 
reviewed for verification of agreement with data entered into the EDC  system.  It is important for the 
site investigator and their relevant personnel to be available for a sufficient a mount of time  during the 
monitoring visits or audit, if applicable. The site investigator and institution guarantee access to source 
documents by [CONTACT_859376] T en CRC AHQ  or its designee. 
 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197569] (FDAMA) and the Food and Drug Administration Amendments Act (FDAAA), the sponsor- investigator of the trial is solely 
responsible for determining whether the trial and its results are subject to the requirements for submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov
. All results of primary and 
secondary objectives must be posted to CT.gov within a year of completion. The sponsor-investigator has delegated responsibility to Big T en CRC AHQ for registering the trial and posting the results on 
clinicaltrials.gov. MICHR-MIAP will be responsible for submitting FDA Form [ADDRESS_1197570] KEEPI[INVESTIGATOR_1645]  
14.1 Data Management 
Big Ten CRC AHQ  will serve as the Clinical Research Organization  for this trial. Data will be collected 
through a web -based clinical research platform compliant with Good Clinical Practices and Federal 
Rules and Regulations. Big T en CRC AHQ personnel will coordinate and manage data for quality 
control assurance and integrity. All data will be collected and entered into the EDC  system by [CONTACT_740751].    
14.2 Case Report Forms and Submission  
Generally, clinical data will be electronically captured in the EDC system and correlative result s will be 
captured in the EDC  system or other secure database(s). If procedures on the study calendar are 
performed for standard of care, at minimum, that data will be captured in the source document. Select 
standard of care data will also be captured in the EDC system, according to study- specific objectives. 
Please see the Data and Safety Oversight Process (DSOP) guidelines for further details.  
 The completed dataset is housed at Big T en CRC AHQ and is the sole property of the sponsor-
investigator â€™s institution . It should not be made available in any form to third parties, except for 
authorized representatives of appropriate Health/Regulatory Authorities, without written permission from the sponsor-investigator and Big T en CRC AHQ . After the initial publication, the complete data 
set will be available to all B ig Ten CRC institutions.  
14.[ADDRESS_1197571] Retention  
To enable evaluations and/or audits from Health Authorities/Big T en CRC AHQ, the site  investigator 
agrees to keep records, including the identity of all subjects  (sufficient information to link records; e.g., 
hospi[INVESTIGATOR_1097]), all original signed informed consent forms, copi[INVESTIGATOR_129299], and detailed records of drug disposition.  All so urce documents are to remain in the subjectâ€™s file and 
retained by [CONTACT_859379]. No records will be 
destroyed until Big T en CRC AHQ confirms destruction is permitted.  
 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197572] information.  All records identifying the 
subjects will be kept confidential and, to the extent permitted by [CONTACT_29695]/or regulations, 
will not be made publicly available. Information collected w ill be maintained on secure, password 
protected electronic systems. Paper files that contain personal information will be kept in locked and 
secure locations only accessible to the study site personnel.   Subjects will be informed in writing that some organizations including the sponsor-investigator and 
his/her research associates, Big Ten CRC AHQ , Bristol-Myers Squibb IRB, or government agencies, 
like the FDA, may inspect their medical records to verify the information collected, and that all personal information made available for inspection will be handled in strictest confidence and in accordance with local data protection laws.  
 If the results of the study are published, the subjects â€™s identity will remain confidential.  
15. ETHICS  
15.[ADDRESS_1197573] (IRB) Approval 
The final study protocol and the final version of the informed consent form must be approved in writing by [CONTACT_2717].  The site  investigator must submit written approval by [CONTACT_859380] T en CRC AHQ before 
he or she can enroll subjects  into the study.   
 The site investigator is responsible for informing the IRB of any amendment to the protocol in 
accordance with local requirements.  In addition, the IRB must approve all advertising used to recrui t 
subjects for the study.  The protocol must be re-approved by [CONTACT_859381].  
 Progress reports and notifications of adverse events  will be provided to the IRB according to local 
regulations and guidelines. 
15.[ADDRESS_1197574] of the study will be in compliance with ICH Good Clinical Practice, and with all 
applicable federal (including 21 CFR parts 56 & 50) , state, or local laws.  
 
15.[ADDRESS_1197575]â€™s signed and dated informed consent must be obtained before conducting any procedure 
specifically for the study.  The site  investigator must store the original, signed informed consent form.  
A copy of the signed i nformed consent form must be given to the subject . 
   
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 56 of 84 16. REFERENCES  
 
1. Foss, F.M., et al., Peripheral T -cell lymphoma. Blood, 2011. 117(25): p. 6756-67. 
2. Vose, J., et al., International peripheral T- cell and natural killer/T -cell lymphoma study: 
pathology findings and clinical outcomes.  J Clin Oncol, 2008. 26(25): p. 4124-30. 
3. Morgensztern, D., et al., Lack of survival improvement in patients with peripheral T- cell 
lymphoma: a Surveillance, Epi[INVESTIGATOR_623], and End Results analysis. Leuk Lymphoma, 2011. 52(2): p. 194-204. 
4. Weisenburger, D.D., et al., Peripheral T-cell lymphoma, not otherwise specified: a report of [ADDRESS_1197576].  Blood, 2011. 117(12): p. 
3402-8. 
5. Abouyabis, A.N., et al., Incidence and outcomes of the peripheral T-cell lymphoma subtypes in 
the [LOCATION_002]. Leuk Lymphoma, 2008. 49(11): p. 2099-107. 
6. Morton, L.M., et al., Lymphoma incidence patterns by [CONTACT_197781], 1992-
2001. Blood, 2006. 107(1): p. 265-76. 
7. Briski, R., et al., The role of front-line anthracycline-containing chemotherapy regimens in 
peripheral T- cell lymphomas.  Blood Cancer J, 2014. 4: p. e214. 
8. O'Connor, O.A., et al., Belinostat in Patients With Relapsed or Refractory Peripheral T- Cell 
Lymphoma: Results of the Pi[INVESTIGATOR_700378] (CLN -19) Study. J Clin Oncol, 2015. 33(23): 
p. 2492-9. 
9. O'Connor, O.A., et al., Pralatrexate in patients with relapsed or refractory peripheral T- cell 
lymphoma: results from the pi[INVESTIGATOR_460308]. J Clin Oncol, 2011. 29(9): p. 1182-9. 
10. Pi[INVESTIGATOR_79577], R.L., et al., Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. 
Blood, 2011. 117(22): p. 5827-34. 
11. Coiffier, B., et al., Results from a pi[INVESTIGATOR_22735], open-label, phase II study of romidepsin in relapsed or 
refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol, 2012. 30(6): p. 631-6. 
12. Mak, V., et al., Survival of patients with peripheral T- cell lymphoma after first relapse or 
progression: spectrum of disease and rare long- term survivors.  J Clin Oncol, 2013. 31(16): p. 
1970-6. 
13. Briski, R., et al., Survival in Patients with Limited -stage Peripheral T-cell Lymphomas. Leuk 
Lymphoma, 2014: p. 1-17. 
14. Phillips, T., S. Devata, and R.A. Wilcox, Challenges and opportunities for checkpoint blockade 
in T-cell lymphoproliferative disorders. J Immunother Cancer, 2016. 4: p. 95. 
15. Pro, B., et al., Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic 
anaplastic large-cell lymphoma: results of a phase II study. J Cl in Oncol, 2012. 30(18): p. 2190-
6. 
16. Horwitz, S.M., et al., Objective responses in relapsed T -cell lymphomas with single-agent 
brentuximab vedotin. Blood, 2014. 123(20): p. 3095-100. 
17. Hughes, C.F., et al., Lack of durable disease control with chemotherapy for mycosis fungoides 
and Sezary syndrome: a comparative study of systemic therapy. Blood, 2015. 125(1): p. 71-81. 
18. Wilcox, R.A., Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and 
management. Am J Hematol, 2016. 91(1): p. 151-65. 
19. Lesokhin, A.M., et al., Nivolumab in Patients With Relapsed or Refractory Hematologic 
Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol, 2016. 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 57 of 84 20. Kim, Y., A Phase 2 Study of Pembrolizumab for the Treatment of Relapsed/Refractory MF/SS. 
Presented at: T -cell Lymphoma Forum, 2016. 
21. Wilcox, R.A., et al., Monocytes promote tumor cell survival in T- cell lymphoproliferative 
disorders and are impaired in their ability to differentiate into mature dendri tic cells. Blood, 
2009. 114(14): p. 2936-44. 
22. Wilcox, R.A., et al., B7 -H1 (PD-L1, CD274) suppresses host immunity in T- cell 
lymphoproliferative disorders. Blood, 2009. 114(10): p. 2149-58. 
23. Wilcox, R.A., et al., The B7 homologues and their receptors in hematologic malignancies. Eur J 
Haematol, 2012. 88(6): p. 465-75. 
24. Wang, T., et al., GATA-[ADDRESS_1197577] 
molecular and clinical features. Blood, 2014. 123(19): p. 3007-15. 
25. Wilcox, R.A., Cancer-associated myeloproliferation: old association, new therapeutic target. 
Mayo Clin Proc, 2010. 85(7): p. 656-63. 
26. Wilcox, R.A., A three-signal model of T-cell lymphoma pathogenesis. Am J Hematol, 2016. 
91(1): p. 113-22. 
27. McClanahan, F., et al., PD -L1 checkpoint blockade prevents immune dysfunction and leukemia 
development in a mouse model of chronic lymphocytic leukemia. Blood, 2015. 126(2): p. 203-11. 
28. Hume, D.A. and K.P. MacDonald, Therapeutic applications of macrophage colony- stimulating 
factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood, 2012. 119(8): p. 
1810-20. 
29. Pyonteck, S.M., et al., CSF-1R inhibition alters macrophage polarization and blocks glioma 
progression. Nat Med, 2013. 19(10): p. 1264-72. 
30. Ries, C.H., et al., Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a 
strategy for cancer therapy.  Cancer Cell, 2014. 25(6): p. 846-59. 
31. Mok, S., et al., Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell 
transfer immunotherapy. Cancer Res, 2014. 74 (1): p. 153-61. 
32. Stafford, J.H., et al., Colony stimulating factor 1 receptor inhibition delays recurrence of 
glioblastoma after radiation by [CONTACT_859382]. Neuro Oncol, 2015. 
33. Polk, A., et al., Colony-stimulating Factor-1 Receptor is Required for Nurse- like Cell Survival in 
Chronic Lymphocytic Leukemia. Clin Cancer Res, 2016. 
34. Hanna, B.S., et al., Depletion of CLL-associated patrolling monocytes and macrophages controls 
disease development and repairs immune dysfunction in vivo. Leukemia, 2015. 
35. Sluijter, M., et al., Inhibition of CSF- 1R supports T -cell mediated melanoma therapy. PLoS One, 
2014. 9(8): p. e104230. 
36. Lamprecht, B., et al., Derepression of an endogenous long terminal repeat activates the CSF1R 
proto-oncogene in human lymphoma. Nat Med, 2010. 16(5): p. 571-9, 1p following 579. 
37. Keizer, R.J., et al., Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin 
Pharmacokinet, 2010. 49 (8): p. 493-507. 
38. Lee, J.I., et al., CYP -mediated therapeutic protein-drug interactions: clinical findings, proposed 
mechanisms and regulatory implications. Clin Pharmacokinet, 2010. 49 (5): p. 295-310. 
39. Hamilton, J.A. and P.P. Tak, The dynamics of macrophage lineage populations in inflammatory 
and autoimmune diseases. Arthritis Rheum, 2009. 60(5): p. 1210-21. 
40. Masteller, E.L. and B.R. Wong, Targeting IL-34 in chronic inflammation. Drug Discov Today, 
2014. 19(8): p. 1212-6. 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197578], Tumor-associated macrophages: from mechanisms to therapy. 
Immunity, 2014. 41(1): p. 49-61. 
42. Komohara, Y., M. Jinushi, and M. Takeya, Clinical significance of macrophage heterogeneity in 
human malignant tumors. Cancer Sci, 2014. 105(1): p. 1 -8. 
43. Cassier, P.A., et al., CSF1R inhibition with emactuzumab in locally advanced diffuse- type 
tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 
study. Lancet Oncol, 2015. 16(8): p. 949-56. 
44. Zhu, Y., et al., CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves 
response to T-cell checkpoint immunotherapy in pancreatic cancer models.  Cancer Res, 2014. 
74(18): p. 5057-69. 
45. Wherry, E.J. and M. Kurachi, Molecular and cellular insights into T cell exhaustion. Nat Rev 
Immunol, 2015. 15(8): p. 486-99. 
46. Schietinger, A. and P.D. Greenberg, Tolerance and exhaustion: defining mechanisms of T cell 
dysfunction. Trends Immunol, 2014. 35(2): p. 51-60. 
47. Wilcox, R.A., A three signal model of T-cell lymphoma pathogenesis. Am J Hematol, 2015. 48. Robins, H.S., et al., Comprehensive assessment of T- cell receptor beta -chain diversity in 
alphabeta T cells. Blood, 2009. 114(19): p. 4099-107. 
49. Weng, W.K., et al., Minimal residual disease monitoring with high-throughput sequencing of T 
cell receptors in cutaneous T cell lymphoma. Sci Transl Med, 2013. 5(214): p. 214ra171. 
50. Sufficool, K.E., et al., T- cell clonality assessment by [CONTACT_11398] -generation sequencing impr oves 
detection sensitivity in mycosis fungoides.  J Am Acad Dermatol, 2015. 73(2): p. 228-36 e2. 
51. Kirsch, I.R., et al., TCR sequencing facilitates diagnosis and identifies mature T cells as the cell 
of origin in CTCL. Sci Transl Med, 2015. 7(308): p. 308ra158. 
52. Clemente, M.J., et al., Deep sequencing of the T- cell receptor repertoire in CD8+ T -large 
granular lymphocyte leukemia identifies signature [CONTACT_859394]. Blood, 2013. 122(25): p. 4077-85. 
53. Schmielau, J. and O.J. Finn, Activated granulocytes and granulocyte-derived hydrogen peroxide 
are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res, 2001. 61 (12): p. 4756-60. 
54. Filipazzi, P., et al., Identification of a new subset of myeloid suppressor cells in peripheral blood 
of melanoma patients with modulation by a granulocyte- macrophage colony -stimulation factor -
based antitumor vaccine.  J Clin Oncol, 2007. 25(18): p. 2546-53. 
55. Hoechst, B., et al., A new population of myeloid-derived suppressor cells in hepatocellular 
carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology, 2008. 135(1): p. 234-43. 
56. Rodriguez, P.C., et al., Arginase I-producing myeloid-derived suppressor cells in renal cell 
carcinoma are a subpopulation of activated granulocytes. Cancer Res, 2009. 69(4): p. 1553-60. 
57. Almand, B., et al., Increased production of immature myeloid cells in cancer patients: a 
mechanism of immunosuppression in cancer. J Immunol, 2001. 166(1): p. 678-89. 
58. Ilkovitch, D. and D.M. Lopez, The liver is a site for tumor -induced myeloid-derived suppressor 
cell accumulation and immunosuppression. Cancer Res, 2009. 69(13): p. 5514-21. 
59. Sinha, P., et al., Proinflammatory S100 proteins regulate the accumulation of myeloid- derived 
suppressor cells.  J Immunol, 2008. 181(7): p. 4666-75. 
60. Marigo, I., et al., Tumor-induced tolerance and immune suppression by [CONTACT_859383].  Immunol Rev, 2008. 222: p. 162-79. 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 59 of 84 61. Zhu, B., et al., CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune 
encephalomyelitis.  J Immunol, 2007. 179(8): p. 5228-37. 
62. Delano, M.J., et al., MyD88 -dependent expansion of an immature GR-1(+)CD11b(+) population 
induces T cell suppression and Th2 polarization in sepsis. J Exp Med, 2007. 204(6): p. 1463-74. 
63. Kusmartsev, S., S. Nagaraj, and D.I. Gabrilovich, Tumor-associated CD8+ T cell tolerance 
induced by [CONTACT_167666]- derived immature myeloid cells.  J Immunol, 2005. 175(7): p. 4583-92. 
64. Zea, A.H., et al., Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: 
a mechanism of tumor evasion. Cancer Res, 2005. 65(8): p. 3044-8. 
65. Serafini, P., et al., High -dose granulocyte-macrophage colony- stimulating factor -producing 
vaccines impair the immune response through the recruitment of myeloid suppressor cells. 
Cancer Res, 2004. 64 (17): p. 6337-43. 
66. Voisin, M.B., et al., Both expansion of regulatory GR1+ CD11b+ myeloid cells and anergy of T 
lymphocytes participate in hyporesponsiveness of the lung-associated immune system during acute toxoplasmosis. Infect Immun, 2004. 72(9): p. 5487-92. 
67. Satoh, A., et al., Human leukocyte antigen-DR expression on peripheral monocytes as a 
predictive marker of sepsis during acute pancreatitis. Pancreas, 2002. 25(3): p. 245-50. 
68. Dolcetti, L., et al., Hierarchy of immunosuppressive strength among myeloid-derived suppressor 
cell subsets is determined by [CONTACT_68460] -CSF. Eur J Immunol, 2010. 40(1): p. 22-35. 
69. Youn, J.I., et al., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol, 
2008. 181(8): p. 5791-802. 
70. Movahedi, K., et al., Identification of discrete tumor -induced myeloid- derived suppressor cell 
subpopulations with distinct T cell- suppressive activity.  Blood, 2008. 111(8): p. 4233-44. 
71. Li, H., et al., Cancer -expanded myeloid- derived suppressor cells induce anergy of NK cells 
through membrane-bound TGF-beta 1. J Immunol, 2009. 182(1): p. 240-9. 
72. Huang, B., et al., Gr -1+CD115+ immature myeloid suppressor cells mediate the development of 
tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res, 2006. 66(2): p. 1123-31. 
73. Hu, C.E., et al., Up -regulated myeloid-derived suppressor cell contributes to hepatocellular 
carcinoma development by [CONTACT_859384]. Scand J Gas troenterol, 2011. 46(2): 
p. 156-64. 
74. Mao, Y., et al., Melanoma-educated CD14+ cells acquire a myeloid- derived suppressor cell 
phenotype through COX-2- dependent mechanisms. Cancer Res, 2013. 73 (13): p. 3877-87. 
75. Srivastava, M.K., et al., Myeloid-derived suppressor cells inhibit T-cell activation by [CONTACT_859385].  Cancer Res, 2010. 70(1): p. 68 -77. 
76. Lindau, D., et al., The immunosuppressive tumour network: myeloid- derived suppressor cells, 
regulatory T cells and natural killer T cells.  Immunology, 2013. 138(2): p. 105-15. 
77. Tarhini, A.A., et al., Immune monitoring of the circulation and the tumor microenvironment in 
patients with regionally advanced melanoma receiving neoadjuvant ipi[INVESTIGATOR_125]. PL oS One, 
2014. 9(2): p. e87705. 
78. Meyer, C., et al., Frequencies of circulating MDSC correlate with clinical outcome of melanoma 
patients treated with ipi[INVESTIGATOR_125]. Cancer Immunol Immunother, 2014. 63 (3): p. 247-57. 
79. Finkelstein, S.E., et al., Changes in dendritic cell phenotype after a new high- dose weekly 
schedule of interleukin -2 therapy for kidney cancer and melanoma. J Immunother, 2010. 33(8): 
p. 817-27. 
80. Kimura, T., et al., MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer 
immunoprevention feasibility study. Cancer Prev Res (Phila), 2013. 6(1): p. 18-26. 
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-[ADDRESS_1197579], R.B., et al., Targeting myeloid-derived suppressor cells with colony stimulating 
factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-
dioxygenase-expressing tumors. EBioMedicine, 2016. 6: p. 50-58. 
82. Cheson, B.D., et al., Refinement of the Lugano Classification lymphoma response criteria in the 
era of immunomodulatory therapy. Blood, 2016. 128(21): p. 2489-2496. 
83. Cheson, B.D., et al., Recommendations for initial evaluation, staging, and response assessment 
of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 2014. 32(27): p. 3059-68. 
   
Big Ten Cancer Research Consortium    Clinical Study Protocol  
    BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 61 of 84 17. APPENDICES  
17.1 Management of toxicities 
These general guidelines constitute guidance to the Site Investigator and may be supplemented by 
[CONTACT_859386]. The guidance applies to all immuno-oncology (I -O) agents 
and regimens. A general principle is that differential diagnoses should be diligently evaluated according 
to standard medical practice. Non -inflammatory etiologies should be considered and appropriately 
treated. Corticosteroids are a primary therapy for immuno-oncology drug- related adverse events. The 
oral equivalent of the recommended IV doses may be considered for ambulatory patients with low- grade 
toxicity. The lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids. Consultation with a medical or surgical specialist, especially prior to an invasive diagnostic or therapeutic procedure, is recommended. The frequency and severity of the related adverse events covered by [CONTACT_70744]-oncology agent or regimen being used. 
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 62 of 84 17.1.1 Gastrointestinal toxicity  management 
 
Gastrointestinal  Adverse Event  Management  
Rule out noninflammatory  causes. If a noninflammatory  cause is identified,  treat accordingly  and continue nivolumab  therapy. Opi[INVESTIGATOR_858]/narcotics  may 
mask symptoms  of perforation.  Infliximab  should not be used in cases of perforation or sepsis. 
Grade of  Diarrhea/Colitis  Management  Treatment  and Follow-Up 
Grade 1: Diarrhea:<4  stools/day  
over baseline; Colitis: 
asymptomatic  â€“ Continue cabiralizumab  and nivolumab  
therapy per protocol 
â€“ Symptomatic treatment â€“ Close monitoring for  worsening symptoms  
â€“ Educate patient to report worsening immediately  
If worsens: 
â€“ Treat as Grade 2 or 3/4 
Grade 2: Diarrhea: 4â€“6 stools 
per day over baseline; IV fluids 
indicated <24 hours;  not 
interfering  with ADL; Colitis: 
abdominal  pain; blood in stool â€“ Delay cabiralizumab  and nivolumab  
per protocola 
â€“ Symptomatic treatment If improves  to Grade 1 â‰¤4 days: 
â€“ Resume cabiralizumab  and nivolumab therapy per protocol  
If persists â‰¥5â€“7 days or recurs: 
â€“ 0.5â€“1 mg/kg/day methylprednisolone or oral equivalent 
â€“ When symptoms  improve to Grade 1, taper steroids over at least 1 
month, consider prophylactic antibiotics  for opportunistic 
infections,  and resume cabiralizumab  and nivolumab therapy per 
protocol 
If worsens or persists >3-5 days with oral steroids: 
â€“ Treat as Grade 3 or 4 
Grade 3â€“ 4: Diarrhea (G3): â‰¥7 
stools per day over baseline; 
incontinence;  IV fluids â‰¥24 
hours; interfering  with ADL; 
Colitis (G3): Severe abdominal  
pain, medical intervention  
indicated,  peritoneal  signs 
 
Grade 4: Life-
threatening,  perforation â€“ Delay or Discontinue  cabiralizumab  
and nivolumab  therapy per 
protocolb 
â€“ 1 to 2 mg/kg/day methylprednisolone IV 
or IV equivalentc 
â€“ Add prophylactic antibiotics for 
opportunistic  infections  
â€“ Consider lower endoscopy  if clinically  
indicated If Grade 3 AE improves  to Grade 1 or baseline within 28 days: 
â€“ Taper steroids over at least 1 month 
â€“ Resume dosing of cabiralizumab  and Nivolumab 
If Grade 4: 
â€“ Permanently  discontinue  cabiralizumab  and Nivolumab 
â€“ Continue steroids until Grade 1, then taper steroids over at least 1 month 
If persists >3-5 days, or recurs after improvement:  
â€“ Add infliximab  5 mg/kg (if no contraindications)  
â€“ Follow up until resolution 
â€“ Note: Infliximab  should not  be used in cases of perforation or sepsis 
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued,  taking into  account the safety  and clinical 
benefit to the patient 
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of AE and 
clinical benefit is shown by [CONTACT_4676] 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained clinical 
improvement  is observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to the equivalent  dose of oral 
corticosteroids.  
 
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197580] or ALT >3.0x ULN 
and 
Total bilirubin >2x ULN or 
INR > 1.5 â€“ Discontinue cabiralizumab  and nivolumab per protocol  
â€“ Start steroids â€“ Continue LFT monitoring  per protocol until resolution.  
â€“ Continue monitoring for  and other associated  clinical signs or symptoms  
â€“ Contact [CONTACT_513022]  
â€“ Evaluate for  non drug related causes of the laboratory abnormalities  (e.g. 
obstruction,  viral infection,  Gilbertâ€™s disease, etc) 
â€“ Under selected circumstances  (e.g alternative etiology  is identified),  patient 
may receive additional therapy only after consultation  and agreement  
between the Sponsor/MM  and the investigator  if receiving additional  
treatment with cabiralizumab  and nivolumab  is in the best interest of the 
patient (e.g if the subject has demonstrated  a response to therapy) 
AST or ALT > 5 to â‰¤ [ADDRESS_1197581] 
and 
Total bilirubin â‰¤ [ADDRESS_1197582] â€“ Continue cabiralizumab  and nivolumab  therapy if 
there are no clinical signs of significant  muscle or 
hepatic damage 
â€“ Increase frequency  of monitoring of AST, ALT, 
bilirubin, alkaline phosphatase and  INR (every 48-
72 hours or more frequently,  as clinically 
indicated)  
â€“ Monitor for other clinical symptoms  (fatigue, 
nausea, vomiting,  abdominal  pain, fever, rash, 
and/or eosinophilia)  â€“ Contact [CONTACT_859387]  
â€“ Contact [CONTACT_859388] a concurrent  increase of 
bilirubin, AST, ALT, or alkaline phosphatase 
â€“ Notify the Sponsor Investigator  if there is an AST or ALT increase > [ADDRESS_1197583] 
â€“ Frequency  of retesting can  decrease to once a week or less if abnormalities  
stabilize or the trial drug has been discontinued and the subject  is 
asymptomatic  
â€“ Consider gastroenterology or hepatology  referral 
AST or ALT > 12 to â‰¤ [ADDRESS_1197584] 
and 
Total bilirubin â‰¤ [ADDRESS_1197585] 
or 
Isolated total bilirubin > 2 to â‰¤ 
[ADDRESS_1197586] â€“ Delay cabiralizumab  and nivolumab  therapy 
per protocola 
â€“ Increase frequency  of monitoring  of (including  but 
not limited to) AST, ALT, bilirubin, alkaline 
phosphatase  and INR (every 48-72 hours or more 
frequently,  as clinically indicated)  
â€“ If there is a 2-fold ALT increase compared  to 
the previous measurement,  start steroids 
immediately  
â€“ Consider steroid treatment  on any total bilirubin 
increase of over 2.0x ULN 
â€“ If there is a concurrent  increase of alkaline 
phosphatase  along with ALT, start steroids 
immediately  
â€“ Monitor for other clinical symptoms  (fatigue, 
nausea, vomiting,  abdominal  pain, fever, rash, 
and/or eosinophilia)  If AST/ALT  return to â‰¤ [ADDRESS_1197587] within â‰¤ 7 days: 
â€“ Resume routine monitoring  
â€“ Resume cabiralizumab  and nivolumab  therapy at same dose level per 
protocol 
If elevations  persist and remain at the same level  > 7 days but < 28 days: 
â€“ Start steroids immediately  and discontinue  further dosing 
â€“ Continue monitoring and  consider dosing the subject with nivolumab  therapy 
at the same dose level 
Consider tapering steroids over at least [ADDRESS_1197588] at the same level > 28 days or worsen: 
â€“ Discontinue cabiralizumab  and nivolumab therapy per protocol 
â€“ 0.5-1 mg/kg/day methylprednisolone or oral equivalent  and when LFT  
returns to Grade [ADDRESS_1197589] 1 month 
â€“ Consider prophylactic antibiotics  for opportunistic infections  
â€“ Discuss with Sponsor Investigator  
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197590] or ALT > [ADDRESS_1197591] 
or 
Total bilirubin >[ADDRESS_1197592] â€“ Discontinue cabiralizumab  and nivolumab therapyb 
â€“ Increase frequency  of monitoring  to every 1 to 2 days 
â€“ Consider 1 to 2 mg/kg/day methylprednisolone IV or 
IV equivalentc 
â€“ Consider adding prophylactic antibiotics for 
opportunistic  infections  
â€“ Consult gastroenterologist  and hepatologist,  if clinically 
indicated If returns to Grade 2: 
â€“ Consider steroid taper  over at least [ADDRESS_1197593] been  started 
If does not improve in >3â€“5 days, worsens, or rebounds:  
â€“ Consider adding mycophenolate  mofetil 1 g BID 
â€“ If no response within  an additional  3â€“5 days, consider other  
immunosuppressants  per local guidelines  
â€“ Follow up until resolution  
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued,  taking into  account the safety  and clinical benefit to the patient.  
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of AE and clinical benefit is 
shown by [CONTACT_4676]. 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained clinical improvement  is 
observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to  the equivalent  dose of oral corticosteroids.  
 
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197594] or ALT >3.0x ULN 
and 
Total bilirubin >2x ULN or 
INR 
> 1.5 â€“ Discontinue cabiralizumab  and nivolumab  therapy per 
protocol 
â€“ Start steroids â€“ Continue LFT monitoring  per protocol until resolution.  
â€“ Continue monitoring for  and other associated  clinical 
signs or symptoms  
â€“ Contact [CONTACT_513022]  
â€“ Evaluate for  non drug related causes of the laboratory  
abnormalities  (e.g. obstruction,  viral infection,  Gilbertâ€™s 
disease, etc)  
â€“ Under selected circumstances  (e.g alternative etiology  is 
identified),  patient may receive additional therapy only 
after consultation and agreement  between the 
Sponsor/MM  and the investigator  if receiving additional  
treatment  with cabiralizumab  and nivolumab  is in the 
best interest of the patient (e.g if the subject has 
demonstrated a response to therapy) 
AST or ALT > 5 to â‰¤ [ADDRESS_1197595] 
and 
Total bilirubin â‰¤ [ADDRESS_1197596] â€“ Continue cabiralizumab  and nivolumab  therapy if there 
are no clinical signs of significant  muscle or hepatic 
damage 
â€“ Increase frequency  of monitoring  of AST, ALT, 
bilirubin, alkaline phosphatase and INR (every 48-
72 hours or more frequently,  as clinically indicated)  
â€“ Monitor for other clinical symptoms  (fatigue, nausea, 
vomiting,  abdominal  pain, fever, rash, and/or 
eosinophilia)  â€“ Contact [CONTACT_859389]  
â€“ Contact [CONTACT_859388] a concurrent  
increase of bilirubin, AST, ALT, or alkaline phosphatase  
â€“ Notify the Sponsor Investigator  if there is an AST or ALT 
increase > [ADDRESS_1197597] 
â€“ Frequency  of retesting can  decrease to once a week or less 
if abnormalities  stabilize or the trial drug has been 
discontinued and the subject is asymptomatic  
â€“ Consider gastroenterology  or hepatology  referral 
 
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197598] or ALT > 12 to â‰¤ [ADDRESS_1197599] 
and 
Total bilirubin â‰¤ [ADDRESS_1197600] 
or 
Isolated total bilirubin > 3.0 to â‰¤ 
[ADDRESS_1197601] â€“ Delay cabiralizumab  and nivolumab  therapy per protocola 
â€“ Increase frequency  of monitoring  of (including  but not limited 
to) AST, ALT, bilirubin, alkaline phosphatase and INR (every 
48-72 hours or more frequently,  as clinically indicated)  
â€“ If there is a 2-fold ALT increase compared  to the previous 
measurement,  start steroids immediately  
â€“ Consider steroid treatment  on any total bilirubin increase of over 
2.0x ULN 
â€“ If there is a concurrent  increase of alkaline phosphatase along  
with ALT, start steroids immediately  
â€“ Monitor for other clinical symptoms  (fatigue, nausea, vomiting, 
abdominal  pain, fever, rash, and/or eosinophilia)  If AST/ALT  return to â‰¤ [ADDRESS_1197602] within â‰¤ 7 days: 
â€“ Resume routine monitoring,  resume cabiralizumab  and nivolumab  
therapy at same dose level per protocol 
If elevations  persist and remain at the same level  > 7 days but < 
28 days: 
â€“ Start steroids immediately  and discontinue  further dosing 
â€“ Continue monitoring and  consider dosing the subject with 
nivolumab  therapy at the same dose level  
â€“ Consider tapering steroids over at least [ADDRESS_1197603] at the same level >28 days or worsen: 
â€“ Discontinue cabiralizumab  and  nivolumab therapy per protocol  
â€“ 0.5â€“1 mg/kg/day methylprednisolone or oral equivalent  and when 
LFT returns to Grade [ADDRESS_1197604] 1 
month 
â€“ Consider prophylactic antibiotics  for opportunistic infections  
â€“ Discuss with Sponsor Investigator  
AST or ALT > [ADDRESS_1197605] 
or 
Total Bilirubin > [ADDRESS_1197606] â€“ Discontinue cabiralizumab  and nivolumab therapyb 
â€“ Increase frequency  of monitoring  to every 1â€“2 days 
â€“ Consider 1 to 2 mg/kg/day methylprednisolone IV or IV 
equivalentc 
â€“ Consider adding prophylactic antibiotics for opportunistic  
infections  
â€“ Consult gastroenterologist  and hepatologist,  if clinically 
indicated If returns to Grade 2 or baseline:  
â€“ Consider steroid taper  over at least [ADDRESS_1197607] been  
started 
If does not improve in >3â€“5 days, worsens, or rebounds:  
â€“ Consider adding mycophenolate  mofetil 1 g BID 
â€“ If no response within  an additional  3â€“5 days, consider other  
immunosuppressants  per local guidelines  
â€“ Follow up until resolution  
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued,  taking into  account the safety  and clinical benefit to the patient.  
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of AE and clinical benefit is 
shown by [CONTACT_4676]. 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained clinical improvement  is 
observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to  the equivalent dose of oral corticosteroids. 
 
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 67 of 84 17.1.4 Renal toxicity management 
 
Renal Adverse Event  Management  
Rule out noninflammatory  causes. If a noninflammatory  cause is identified,  treat accordingly  and continue nivolumab  therapy. 
Grade of Creatinine  Elevation  Management  Follow-Up 
Grade 1: Creatinine >1.0x  to 
1.5x baseline; >1x ULN to 
1.5x ULN â€“ Continue cabiralizumab  and nivolumab  
therapy at the same dose level per 
protocol 
â€“ Monitor creatinine weekly  If returns to baseline: 
â€“ Resume routine creatinine monitoring per protocol 
If worsens: 
â€“ Follow as stated below 
Grade 2: Creatinine  >1.5x to 
3.0x baseline; >1.[ADDRESS_1197608] â€“ Delay cabiralizumab  and nivolumab  
therapy per protocola 
â€“ Monitor creatinine every  2 to 3 days 
â€“ 0.5 to 1 mg/kg/day methylprednisolone 
IV or oral equivalentc 
â€“ Consider renal biopsy if clinically indicated If returns to Grade 1 or baseline before the next dosing visit: 
â€“ Taper steroids over at least 1 month, consider prophylactic antibiotics  for 
opportunistic  infections,  and resume cabiralizumab  and nivolumab  
therapy at the same dose level 
â€“ Routine creatinine monitoring  per protocol  
If elevations  persist >14 days or worsen:  
â€“ Treat as Grade 4 
Grade 3: Creatinine  >3.0 x 
baseline; >3.0x ULN to 6.0x 
ULN â€“ Delay cabiralizumab  and nivolumab  
therapy per protocola 
â€“ Monitor creatinine every  2 to 3 days 
â€“ 0.5 to 1 mg/kg/day methylprednisolone 
IV or oral equivalentc 
â€“ Consider renal biopsy if clinically indicated If returns to Grade 1 or baseline before the next dosing visit: 
â€“ Taper steroids over at least 1 month, consider prophylactic antibiotics  for 
opportunistic  infections,  and resume cabiralizumab  and nivolumab  
therapy at the same dose level 
â€“ Routine creatinine monitoring  per protocol 
If elevations  persist > 14 days or worsen: 
â€“ Treat as Grade 4 
Grade 4: Creatinine >6.0x  ULN â€“ Discontinue cabiralizumab  and 
nivolumab  therapy per protocolb 
â€“ 1 to 2 mg/kg/day methylprednisolone IV 
or IV equivalentc 
â€“ Consult nephrologist  
â€“ Consider renal biopsy if clinically indicated If returns to baseline or Grade 1: 
â€“ Taper steroids over at least 1 month and add prophylactic 
antibiotics  for opportunistic  infections  
If worsens: 
â€“ Follow up until resolution 
â€“ Clinical referrals as needed 
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued,  taking into  account the safety  and clinical benefit 
to the patient.  
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of AE and 
clinical benefit is shown by [CONTACT_4676]. 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained clinical 
improvement  is observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to the equivalent  dose of oral 
corticosteroids.  
 
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 68 of 84 17.1.5 Pulmonary toxicity management 
Pulmonary  Adverse Event Management  
Rule out noninflammatory  causes. If a noninflammatory  cause is identified,  treat accordingly  and continue nivolumab  therapy. Evaluate with  imaging 
and pulmonary consultation.  
Grade of Pneumonitis  Management  Follow-Up 
Grade 1: Radiographic  
changes only â€“ Consider delay of cabiralizumab  and nivolumab  
therapy 
â€“ Monitor for symptoms  every 2 to 3 days 
â€“ Consider pulmonary  and infectious  disease consults  â€“ Re-image at least every 3 weeks 
If worsens: 
â€“ Treat as Grade 2 or 3â€“4 
Grade 2: Mild to moderate 
new symptoms  â€“ Delay cabiralizumab  and nivolumab  
therapy per protocola 
â€“ Pulmonary  and infectious  disease consults  
â€“ Monitor symptoms  daily, consider hospi[INVESTIGATOR_059]  
â€“ 1 mg/kg/day methylprednisolone  IV or oral  
equivalent  
â€“ Consider bronchoscopy,  lung biopsy, if 
clinically indicated â€“ Re-image every 1â€“3 days 
If improves  <14 days: 
â€“ When symptoms  return to near baseline, taper steroids over at least 
1 month, consider prophylactic antibiotics for opportunistic 
infections,  and resume cabiralizumab  and nivolumab therapy 
per protocol  
If does not improve after 2 weeks or worsens:  
â€“ Treat as Grade 3â€“4 
Grade 3â€“ 4: Severe new 
symptoms;  New/worsening  
hypoxia; 
Life-threatening  â€“ Discontinue cabiralizumab  and nivolumab  
therapy per protocolb 
â€“ Hospi[INVESTIGATOR_059]  
â€“ Pulmonary  and infectious  disease consults  
â€“ 2 to 4 mg/kg/day methylprednisolone 
IV or IV equivalentc 
â€“ Add prophylactic antibiotics for opportunistic 
infections  
â€“ Consider bronchoscopy,  lung biopsy if 
clinically indicated If improves  to baseline: 
â€“ Taper steroids over at least 6 weeks 
If does not improve after  48 hours or worsens:  
â€“ Add additional  immunosuppression  (e.g. cyclophosphamide,  
IVIG, or mycophenolate mofetil)  
â€“ Follow up until resolution 
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued,  taking into  account the safety  and clinical benefit 
to the patient.  
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of AE and 
clinical benefit is shown by [CONTACT_4676]. 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained clinical 
improvement  is observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to the equivalent  dose of oral 
corticosteroids.  
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 69 of 84 17.1.6 Endocrinopathy toxicity management 
 
Endocrinopathy  Adverse Event  Management  
Rule out noninflammatory  causes. If a noninflammatory  cause is identified,  treat accordingly  and continue nivolumab  therapy. Consider visual field 
testing, endocrinology consultation,  and imaging. 
Description  Management  Follow-Up 
Asymptomatic  TSH elevation â€“  Continue cabiralizumab  and nivolumab  therapy per 
protocol If TSH <0.5x LLN, or TSH >2x ULN, or consistently  out of 
range in 2 subsequent  measurements:  
â€“ Consider endocrinology  consult 
Symptomatic endocrinopathy  â€“ Evaluate endocrine  function 
â€“ Consider pi[INVESTIGATOR_859342]/pi[INVESTIGATOR_362908]: 
â€“ Delay cabiralizumab  and nivolumab therapy per protocola 
â€“ 1 to 2 mg/kg/day methylprednisolone IV or PO 
equivalentc 
â€“ Initiate appropriate hormone therapy 
No abnormal  lab/pi[INVESTIGATOR_859343]: 
â€“ Repeat labs in 1â€“3 weeks and MRI in 1 month If improves  within 28 days (with or without  
hormone  replacement):  
â€“ Taper steroids over at least 1 month and consider 
prophylactic  antibiotics  for opportunistic infections  
â€“ Resume cabiralizumab  and nivolumab therapy per protocol  
â€“ Patients with adrenal insufficiency may need to continue 
steroids with mineralocorticoid  component  
If persists for over 28 days: 
â€“ Delay cabiralizumab  and nivolumab therapy 
â€“ Continue steroids as needed 
â€“ Upon resolution,  discuss with Sponsor Investigator  if 
patients are clinically stable on further dose delay  and 
discontinuation  
â€“ Follow up until resolution  or return to baseline 
Suspi[INVESTIGATOR_43822] 
(e.g. severe dehydration,  
hypotension,  shock out of 
proportion to current illness) â€“ Delay or discontinue  cabiralizumab  and nivolumab  
therapy per protocola,b 
â€“ Rule out sepsis 
â€“ Stress dose of IV steroids with mineralocorticoid  activity 
â€“ IV fluids 
â€“ Consult endocrinologist  
â€“ If adrenal crisis is ruled out, treat as above for  
symptomatic  endocrinopathy   
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued,  taking into  account the safety  and clinical benefit 
to the patient.  
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of AE and 
clinical benefit is shown by [CONTACT_4676]. 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained clinical 
improvement  is observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to the equivalent  dose of oral 
corticosteroids.  
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 70 of 84 17.1.7 Skin toxicity management 
 
Skin Adverse Event  Management  
Rule out noninflammatory  causes. If a noninflammatory  cause is identified,  treat accordingly  and continue nivolumab  therapy. 
Grade of  Rash Management  Follow-Up 
Grade 1â€“ 2: Covering â‰¤30%  BSAd â€“ Symptomatic therapy (e.g. 
antihistamines,  topi[INVESTIGATOR_8826]) 
â€“ Continue cabiralizumab  and 
nivolumab  therapy per protocol  If persists >1-2 weeks or recurs: 
â€“ Consider skin biopsy 
â€“ Delay cabiralizumab  and nivolumab therapy per protocol  
â€“ Consider 0.5â€“1 mg/kg/day methylprednisolone IV or oral 
equivalent.  
â€“ Once improving ,taper  steroids over at least 1 month, 
consider prophylactic antibiotics for opportunistic  
infections,  and resume cabiralizumab  and nivolumab 
therapy per protocol  
If worsens: 
â€“ Treat as Grade 3â€“4 
Grade 3â€“4: Covering >30% 
BSA; Life-threatening  
consequencesd â€“ Delay or discontinue  cabiralizumab  
and nivolumab therapy per 
protocola,b 
â€“ Consider skin biopsy  and dermatology  
consult 
â€“ 1 to 2 mg/kg/day  IV methylprednisolone 
IV or IV equivalentc If improves  to Grade 1 within 28 days: 
â€“ Taper steroids over at least 1 month and add prophylactic 
antibiotics  for opportunistic  infections  
â€“ Resume cabiralizumab  and nivolumab therapy per protocol  
If Persists >28 days or worsens 
â€“ Consider to discontinue cabiralizumab  and nivolumab  
therapy per protocol 
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued,  taking into  account the safety  and clinical benefit 
to the patient  
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending  drug may be continued,  if there is timely resolution  of AE and 
clinical benefit is shown by [CONTACT_4676] 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained clinical 
improvement  is observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to the equivalent  dose of oral 
corticosteroids.  
d. Refer to NCI CTCAE v5 for term-specific grading criteria.  
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 71 of 84 17.1.8 Neurologic toxicity management 
 
Neurological  Adverse Event  Management  
Grade of  Neurological  Toxicity  Management  Follow-Up 
Grade 1: Asymptomatic  or mild 
symptoms;  Intervention not 
indicated â€“ Continue cabiralizumab  and 
nivolumab  therapy per protocol  If worsens: 
â€“  Treat as Grade 2, 3, or 4 
Grade 2: Moderate symptoms;  
Limiting instrumental ADL â€“ Delay cabiralizumab  and nivolumab  
therapy per protocola 
â€“ Treat symptoms  per local guidelines  
â€“ Consider 0.5 to 1 mg/kg/day 
methylprednisolone IV or 
POc If improves  to baseline within 28 days: 
â€“ Resume cabiralizumab  and nivolumab therapy at same dose 
level per protocol when improved  to baseline 
If worsens or persists after 28 days: 
â€“ Treat as Grade 3-4 
Grade 3â€“4: Severe symptoms;  
limiting self-care ADL;  life-
threatening  â€“ Discontinue cabiralizumab  and 
nivolumab  therapyb 
â€“ Obtain neurology  consult 
â€“ Treat symptoms  per local guidelines  1 to 
2 mg/kg/day IV methylprednisolone or 
POc 
â€“ Add prophylactic antibiotics for 
opportunistic  infections  If improves  to Grade 2: 
â€“ Taper steroids over at least 1 month 
If worsens or atypi[INVESTIGATOR_859344]:  
â€“ Consider IVIG or other immunosuppressive therapi[INVESTIGATOR_859345]  
â€“ Continue follow up until resolution  
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued,  taking into  account the safety  and clinical benefit 
to the patient.  
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of AE and 
clinical benefit is shown by [CONTACT_4676]. 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained clinical 
improvement  is observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to the equivalent  dose of oral 
corticosteroids.  
 
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 72 of 84 17.1.9 Periorbital edema management  
 
Periorbital  Edema Adverse Event Management  
Grade of Periorbital  Edema Management  Follow-Up 
Periorbital  Edema > baseline but 
< Grade 2 â€“ Continue cabiralizumab  and nivolumab  
therapy per protocol 
â€“ Monitor edema weekly If worsens: 
â€“  Follow as stated below 
Grade 2 â€“ Delay cabiralizumab  and nivolumab  
therapy per protocola 
â€“ Start systemic treatment  including steroids,  eye 
drops, or analgesics  as neededc If returns to Grade 1 or baseline before the next dosing visit: 
â€“ Continue systemic treatment 
â€“ Resume cabiralizumab  and nivolumab therapy at same 
dose level without delay 
â€“ Routine eye monitoring  per protocol, if clinically stable 
If swelling persists >14 days but returns back to baseline or  
normal within 28 days: 
â€“ Continue nivolumab  and cabiralizumab  dosing at same level 
â€“ If recurs at Grade 2 or above, discontinue cabiralizumab  and 
nivolumab  therapy 
Grade â‰¥3  â€“ Discontinue cabiralizumab  and nivolumab  
therapy per protocolb 
â€“ Systemic treatment  including  steroids, eye 
drops, or analgesics  as neededc 
â€“ Consult Ophthalmologist  if needed If returns to Grade 1 after discontinuation:  
â€“ Systemic treatment  including  tapering steroids as needed 
â€“ Any follow up and ophthalmology consults, if clinically indicated 
â€“ Monitor and follow up until resolution  
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued,  taking into  account the safety  and 
clinical benefit to the patient. 
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of AE and 
clinical benefit is shown by [CONTACT_4676]. 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained clinical 
improvement  is observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to the equivalent  dose of oral 
corticosteroids.  
 
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 73 of 84 17.1.10 Uveitis management  
Uveitis Adverse Event  Management  
Grade of Uveitis Management  Follow-Up 
Grade 1 â€“ Observe symptoms  
â€“ Continue cabiralizumab  and nivolumab  therapy â€“ Watch for worsening of symptoms  including  visual disturbances,  
light sensitivity,  decrease vision  
â€“ Monitor weekly 
If worsens: 
â€“ Follow as stated below 
Grade 2 â€“ Delay or discontinue  cabiralizumab  and 
nivolumab therapy per protocola,b 
â€“ Start antibiotics  and inflammatory 
medications  including steroidsc 
â€“ Ophthalmologic consult,  if clinically indicated 
â€“ Immunosuppressive agents  (e.g, anti-TNF 
agents such as Infliximab)  If symptoms  resolve within 14 days: 
â€“ Continue cabiralizumab  and nivolumab  therapy at same dose level 
and start tapering of steroid doses 
If symptoms  resolve between  14 -28 days: 
â€“ Consider continuing dosing at  same dose level for nivolumab  and a 
dose level lower for cabiralizumab  on resolution  to baseline or 
Grade 1 and start tapering of steroid doses.  
â€“ If it is Grade 2 drug related uveitis which does not resolve within 14  
days, consider to discontinue study drug(s) 
If symptoms  persist or worsen in 28 days regardless  of 
systemic treatment:  
â€“ Discontinue both cabiralizumab  and nivolumab  therapy 
â€“ Continue monitoring  of symptoms  including  visual disturbances,  
eye pain, and dimness  of vision and follow up until resolution or 
return to baseline 
â€“ Continue steroids, antibiotics,  and other medications  such as 
infliximab,  as clinically indicated 
Grade â‰¥3  â€“ Discontinue cabiralizumab  and nivolumab  
therapy per protocolb 
â€“ Start antibiotics  and inflammatory 
medications  including steroidsc 
â€“ Ophthalmologic consult,  if clinically indicated 
â€“ Immunosuppressive agents  (e.g, anti-TNF 
agents such as Infliximab)  â€“ Discontinue both cabiralizumab  and nivolumab  therapy 
â€“ Continue monitoring  of symptoms  including  visual disturbances,  
eye pain, and dimness of vision and follow up until resolution or 
return to baseline 
â€“ Continue steroids, antibiotics,  and other medications  such as 
infliximab,  as clinically indicated 
â€“ Follow up until resolution 
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued, taking into  account the safety  and 
clinical benefit to the patient 
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of 
AE and clinical benefit is shown by [CONTACT_4676] 
c. Patients on IV steroids may be switched to an equivalent  dose of oral corticosteroids  (e.g. prednisone)  at start of tapering or earlier, once sustained 
clinical improvement  is observed.  Lower bioavailability  of oral corticosteroids  should be taken into account when switching to the equivalent  
dose of oral corticosteroids. 
  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-085 
20SEP2019 rev. Confidential Page 74 of 84 17.2 Laboratory abnormalities  management  
 
Laboratory Abnormalities  Management  (CK and LDH) 
Grade of  Liver 
Test Elevation  Management  Follow-Up 
CK > [ADDRESS_1197609] â€“ Measure CK isoenzymes   
â€“ Obtain EKG to evaluate 
arrhythmia/myocarditis  If CK isoenzymes  are abnormal  
â€“ Check troponin  levels 
â€“ Consider other assessments (including  uromyoglobin and 
echocardiogram ) as clinically indicated 
If CK isoenzymes  are normal 
â€“ Continue dosing, per protocol 
â€“ Monitor CK level as clinically indicated 
CK or LDH > 15 to â‰¤ 
[ADDRESS_1197610] â€“ Delay cabiralizumab  therapy per protocola 
â€“ Measure CK  isoenzyme panel to identify 
source of elevation, if abnormal check 
troponin and consider other assessments as 
clinically indicated  
â€“ Increase frequency  of monitoring  (every 48-72 
hours, or more, as clinically indicated)  
â€“ Obtain EKG to evaluate arrhythmia/myocarditis  
â€“ Notify the Sponsor Investigator  If returns to â‰¤ [ADDRESS_1197611] within â‰¤ 28 days: 
â€“ Resume routine monitoring,  resume cabiralizumab  and nivolumab 
therapy at same dose level per protocol  
â€“ If CK isoenzyme panel is normal continue monitoring the subject.  
â€“ If CK isoenzyme panel is abnormal then consider measuring troponins.  
â€“ If troponins are abnormal,  contact [CONTACT_859390]. 
If elevations  persist at the same level > 28 days or worsen: 
â€“ Discontinue further  dosing 
â€“ Discuss with Sponsor Investigator  
CK or LDH > [ADDRESS_1197612] â€“  Discontinue cabiralizumab  therapy  per protocol 
â€“ Obtain EKG to evaluate arrhythmia/myocarditis â€“  Follow up until resolution  
a. If the AE requiring dose delay was  due to one of the study drugs, the non-offending drug may be continued, taking into  account the safety  and clinical 
benefit to the patient. 
b. If the AE requiring discontinuation  was due to one of the study drugs, the non-offending drug may be continued,  if there is timely resolution  of AE and 
clinical benefit is shown by [CONTACT_859391]-HEM16-085 
20SEP2019 rev. Confidential Page 75 of 84  
17.3 Lugano staging criteria 
 
Stage   Involvement  Extranodal (E) status  
Limited 
I One node or a group of adjacent nodes   Single extranodal lesions without nodal 
involvement  
II Two or more nodal groups on the same side 
of the diaphragm  Stage I or II by [CONTACT_859392]* II as above with "bulky" disease  Not applicable  
Advanced  
III Nodes on both sides of the diaphragm; nodes 
above the diaphragm with spleen involvement  Not applicable  
IV Additional noncontiguous extralymphatic 
involvement  Not applicable  
*Defined as a mass with the largest diameter â‰¥[ADDRESS_1197613] diameter . 
17.4 Eastern Cooperative Group (ECOG) Performance Status Scale 
 
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work  
2 Ambulatory and ca pable of all self -care but unable to carry out any work activities. Up and 
about more than 50% of waking hours  
 
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking  
hours 
[ADDRESS_1197614]-Based Response  
Complete  Response (CR)  
 
Lymph nodes and 
extralymphatic sites  
 
 
      
 
 
  
 
 
Nonmeasured lesion 
 Organ enlargement 
 
New lesions  
 Bone marrow Complete metabolic response  
 Score 1, 2, or 3 with or without a residual mass on 5PS* 
It is recognized that in Waldeyerâ€™s ring or extranodal 
sites with high physiologic uptake or with activation 
within spleen or marrow (eg, with chemotherapy or 
myeloid colony-stimulating factors), uptake may be 
greater than normal mediastinum and/or liver. In this 
circumstance, complete metabolic response may be 
inferred if uptake at sites of initial involvement is no greater than surrounding normal tissue even if the 
tissue has high physiologic uptake 
 Not applicable  
 
Not applicable  
 None 
 
No evidence of FDG- avid disease in marrow Complete radiologic response (all of the following)  
 Target nodes/nodal masses must regress to 1.5 cm in 
LDi 
No extralymphatic sites of disease  
  
 
 
  
 
 
Absent 
 Regress to normal 
 
None 
 
Normal by [CONTACT_5293]; if indeterminate, IHC 
negative 
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197615]-Based Response  
Partial Response (PR)  
 
     Lymph nodes and 
extralymphatic sites  
  
 
 
 
     Nonmeasured lesion  
     Organ enlargement  
  
    New lesions  
 
    Bone marrow  Partial metabolic response  
 Score 4 or 5* with reduced uptake compared with 
baseline and residual mass(es) of any size  
At interim, these findings suggest responding disease At end of treatment, these findings indicate residual 
disease 
 
 
 Not applicable  
 Not applicable  
  
None 
 
Residual uptake higher than uptake in normal marrow 
but reduced comp ared with baseline (diffuse uptake 
compatible with reactive changes from chemotherapy 
allowed). If there are persistent focal changes in the 
marrow in the context of a nodal response, consideration should be given to further evaluation 
with MRI or biopsy o r an interval scan  Partial remission (all of the following)  
 â‰¥ 50% decrease in SPD of up to [ADDRESS_1197616], assign 5 
mm x 5 mm as the default value  
When no longer visible, 0 x 0 mm For a node > 5 mm x 5 mm, but smaller than normal, 
use actual measurement for calculation  
 Absent/normal, regressed, but no increase  
 Spleen must have regressed by > 50% in length 
beyond normal 
 
None 
 Not applicable  
No response or stable 
disease (SD) 
 
     Lymph nodes and 
extralymphatic sites  
  
    Nonmeasured lesion  
     Organ enlargement  
 
    New lesions  
 
    Bone marrow  No metabolic response  
 
 
Score 4 or 5* with no significant change in FDG uptake 
from baseline at interim or end of treatment  
  
Not applicable  
 Not applicable  
 
None 
 
No change from baseline  Stable disease  
  
< 50% decrease from baseline in SPD of up to 6 
dominant, measurable nodes and extranodal sites; no 
criteria for progressive disease are met  
 No increase consistent with progression  
 No increase consistent with progression  
 
None 
 
Not applicable  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197617]-Based Response  
Indeterminate Response 1 
(IR1)  
 
 Increase in the overall tumor burden with SPD â‰¥50% 
of up to [ADDRESS_1197618] 12 weeks of 
therapy, without a clinical deterioration.  
Indeterminate Response 2 
(IR2)  
 
 
 Appearance of new lesions or growth of one or more  
existing lesion(s) â‰¥50% at any time during treatment; 
occurring in the context of lack of overall progression (<50% increase) of overall tumor bu rden, as measured 
by [CONTACT_61904] 6 lesions at any time during the 
treatment  
Indeterminate Response 3 
(IR3) Increase in FDG uptake of 1 or more lesion(s) without a 
concomitant increase in lesion size or number   
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197619]-Based Response  
Progressive D isease (PD) 
 
   Lymph nodes  
 
   Extranodal lesions  
 
 
   
 
  
 
 
 
 
 
  Nonmeasured lesion  
       
   New lesions  
 
 
 
 
 
  
    Bone marrow  Progressive metabolic disease  
 Score 4 or 5* with an increase in intensity of uptake 
from baseline and/or  
New FDG-avid foci consistent with lymphoma at 
interim or end -of-treatment assessment  
  
 
  
 
 
 
 
 
 None 
 
 
New FDG-avid foci consistent with lymphoma rather 
than another etiology (eg, infection, inflammation). If 
uncertain regarding etiology of new lesions, biopsy or 
interval scan may be considered  
  
  
New or recurrent FDG -avid foci Progressive disease requires â‰¥1 of the following  
 [COMPANY_003] progression: 
 
An individual node/lesion must be abnormal with:  
LDi > 1.5 cm and  
Increase by â‰¥ 50% from [COMPANY_003] nadir and  
An increase in LDi or SDi from nadir  
0.5 cm for lesions â‰¤ 2 cm  
1.0 cm for lesions > [ADDRESS_1197620] 
increase by > 50% of the extent of its prior increase beyond baseline (eg, a 15- cm spleen must increase 
to > 16 cm). If no prior splenomegaly, must increase by [CONTACT_2669] 2 cm from baseline  
New or recurrent splenomegaly  
 New or clear progression of preexisting nonmeasured 
lesions 
 
Regrowth of previously resolved lesions  
A new node > 1.5 cm in any axis  
A new ex tranodal site > 1.0 cm in any axis; if < 1.[ADDRESS_1197621]-Based Response  
Abbreviations: 5PS, 5 -point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC, immunohistochemistry; LDi, longest transverse 
diameter of a lesion; MRI, magnetic resonance imaging; PET, positron emission tomography; [COMPANY_003], cross product of the LDi and perpendicular 
diameter; SDi, shortest axis perpendicular to the LDi; SPD, sum of the product of the perpendicular diameters for multiple le sions.  
 
Measured dominant lesions: Up to six of the largest dominant nodes, nodal masses, and extranodal lesions  selected to be clearly measurable in 
two diameters. Nodes should preferably be from disparate regions of the body and should include, where applicable, mediastina l and 
retroperitoneal areas. Non -nodal lesions include those in solid organs (eg, liver, sple en, kidneys, lungs), GI involvement, cutaneous lesions, or 
those noted on palpation. Nonmeasured lesions: Any disease not selected as measured, dominant disease and truly assessable disease should be 
considered not measured. These sites include any nodes, nodal masses, and extranodal sites not selected as dominant or measurable or that do 
not meet the requirements for measurability but are still considered abnormal, as well as truly assessable disease, which is any site of suspected 
disease that would be difficult to follow quantitatively with measurement, including pleural effusions, ascites, bone lesions, leptomeningeal 
disease, abdominal masses, and other lesions that cannot be confirmed and followed by [CONTACT_9661]. In Waldeyerâ€™s ring or in extra nodal sites ( eg, 
GI tract, liver, bone marrow), FDG uptake may be greater than in the mediastinum with complete metabolic response, but should  be no higher 
than surrounding normal physiologic uptake (eg, with marrow activation as a result of chemotherapy or myeloid growth factors).  
 
*PET 5PS: 1, no uptake above background; 2, uptake â‰¤ mediastinum; 3, uptake > mediastinum but â‰¤ liver; 4, uptake moderately > liver; 5, 
uptake markedly > liver and/or new lesions; X, new areas of uptake unlikely to be related to lymphoma.  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197622]-Based Response  
Complete  Response (CR)  
 
Lymph nodes and 
extralymphatic sites  
 
 
      
 
 
  
 
 
Nonmeasured lesion 
 Organ enlargement 
 
New lesions  
 Bone marrow Complete metabolic response  
 Score 1, 2, or 3 with or without a residual mass on 5PS* 
It is recognized that in Waldeyerâ€™s ring or extranodal 
sites with high physiologic uptake or with activation 
within spleen or marrow (eg, with chemotherapy or myeloid colony-stimulating factors), uptake may be 
greater than normal mediastinum and/or liver. In this 
circumstance, complete metabolic response may be 
inferred if uptake at sites of initial involvement is no 
greater than surrounding normal tissue even if the 
tissue has high physiologic uptake 
 Not applicable  
 
Not applicable  
 None 
 
No evidence of FDG- avid disease in marrow  Complete radiologic response (all of the following)  
 Target nodes/nodal masses must regress to 1.5 cm in 
LDi 
No extralymphatic sites of disease  
  
 
 
  
 
 
Absent 
 Regress to normal 
 
None 
 
Normal by [CONTACT_5293]; if indeterminate, IHC 
negative 
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197623]-Based Response  
Partial Response (PR)  
 
     Lymph nodes and 
extralymphatic sites  
  
 
 
 
     Nonmeasured lesion  
     Organ enlargement  
  
    New lesions  
 
    Bone marrow  Partial metabolic response  
 Score 4 or 5* with reduced uptake compared with 
baseline and residual mass(es) of any size  
At interim, these findings suggest responding disease 
At end of treatment, these findings indicate residual 
disease 
 
 
 Not applicable  
 Not applicable  
  
None 
 
Residual uptake higher than uptake in normal marrow 
but reduced compared with baseline (diffuse uptake 
compatible with reactive changes from chemotherapy 
allowed). If there are persistent focal changes in the 
marrow in the context of a nodal response, consideration should be given to further evaluation 
with MRI or biopsy or an interval scan  Partial remission (all of the following)  
 â‰¥ 50% decrease in SPD of up to [ADDRESS_1197624], assign 5 
mm x 5 mm as the default value  
When no longer visible, 0 x 0 mm For a node > 5 mm x 5 mm, but smaller than normal, 
use actual measurement for calculation  
 Absent/normal, regressed, but no increase  
 Spleen must have regressed by > 50% in length 
beyond normal 
 
None 
 Not applicable  
No response or stable 
disease (SD) 
 
     Lymph nodes and 
extralymphatic sites  
  
    Nonmeasured lesion  
     Organ enlargement  
 
    New lesions  
 
    Bone marrow  No metabolic response  
 
 
Score 4 or 5* with no significant change in FDG uptake 
from baseline at interim or end of treatment  
  
Not applicable  
 Not applicable  
 
None 
 
No change from baseline  Stable disease  
  
< 50% decrease from baseline in SPD of up to 6 
dominant, measurable nodes and extranodal sites; no 
criteria for progressive disease are met  
 No increase consistent with progression  
 No increase consistent with progression  
 
None 
 
Not applicable  
Big Ten Cancer Research Consortium      Clinical Study Protocol  
     BTCRC-HEM16-[ADDRESS_1197625]-Based Response  
Progressive D isease (PD) 
 
   Lymph nodes  
 
   Extranodal lesions  
 
 
   
 
  
 
 
 
 
 
  Nonmeasured lesion  
       
   New lesions  
 
 
 
 
 
  
    Bone marrow  Progressive metabolic disease  
 Score 4 or 5* with an increase in intensity of uptake 
from baseline and/or  
New FDG-avid foci consistent with lymphoma at 
interim or end -of-treatment assessment  
  
 
  
 
 
 
 
 
 None 
 
 
New FDG-avid foci consistent with lymphoma rather 
than another etiology (eg, infection, inflammation). If 
uncertain regarding etiology of new lesions, biopsy or 
interval scan may be considered  
  
  
New or recurrent FDG -avid foci Progressive disease requires â‰¥1 of the following  
 [COMPANY_003] progression: 
 An individual node/lesion must be abnormal with:  
LDi > 1.5 cm and  
Increase by â‰¥ 50% from [COMPANY_003] nadir and  
An increase in LDi or SDi from nadir  
0.5 cm for lesions â‰¤ 2 cm  
1.0 cm for lesions > [ADDRESS_1197626] 
increase by > 50% of the extent of its prior increase beyond baseline (eg, a 15- cm spleen must increase 
to > 16 cm). If no prior splenomegaly, must increase by [CONTACT_2669] 2 cm from baseline  
New or recurrent splenomegaly  
 New or clear progressio n of preexisting nonmeasured 
lesions 
 
Regrowth of previously resolved lesions  
A new node > 1.5 cm in any axis  
A new extranodal site > 1.0 cm in any axis; if < 1.[ADDRESS_1197627]-Based Response  
Abbreviations: 5PS, 5 -point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC, immunohistochemistry; LDi, longest transverse 
diameter of a lesion; MRI, magnetic resonance imaging; PET, positron emission tomography; [COMPANY_003], cross product of the LDi and perpendicular 
diameter; SDi, shortest axis perpendicular to the LDi; SPD, sum of the product of the perpendicular diameters for multiple le sions.  
 
Measured dominant lesions: Up to six of the largest dominant nodes, nodal masses, and extranodal lesions  selected to be clearly measurable in 
two diameters. Nodes should preferably be from disparate regions of the body and should include, where applicable, mediastina l and 
retroperitoneal areas. Non -nodal lesions include those in solid organs (eg, liver, sple en, kidneys, lungs), GI involvement, cutaneous lesions, or 
those noted on palpation. Nonmeasured lesions: Any disease not selected as measured, dominant disease and truly assessable disease should be 
considered not measured. These sites include any nodes, nodal masses, and extranodal sites not selected as dominant or measurable or that do 
not meet the requirements for measurability but are still considered abnormal, as well as truly assessable disease, which is any site of suspected 
disease that would be difficult to follow quantitatively with measurement, including pleural effusions, ascites, bone lesions, leptomeningeal 
disease, abdominal masses, and other lesions that cannot be confirmed and followed by [CONTACT_9661]. In Waldeyerâ€™s ring or in extra nodal sites ( eg, 
GI tract, liver, bone marrow), FDG uptake may be greater than in the mediastinum with complete metabolic response, but should  be no higher 
than surrounding normal physiologic uptake (eg, with marrow activation as a result of chemotherapy or myeloid growth factors).  
 
*PET 5PS: 1, no uptake above background; 2, uptake â‰¤ mediastinum; 3, uptake > mediastinum but â‰¤ liver; 4, uptake moderately > liver; 5, 
uptake markedly > liver and/or new lesions; X, new areas of uptake unlikely to be related to lymphoma.  
 